0001410578-22-000917.txt : 20220414 0001410578-22-000917.hdr.sgml : 20220414 20220414172219 ACCESSION NUMBER: 0001410578-22-000917 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220414 DATE AS OF CHANGE: 20220414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Future Health ESG Corp. CENTRAL INDEX KEY: 0001851182 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 862305680 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40788 FILM NUMBER: 22828300 BUSINESS ADDRESS: STREET 1: 8 THE GREEN STREET 2: SUITE # 12081 CITY: DOVER STATE: DE ZIP: 19901 BUSINESS PHONE: 833-388-8734 MAIL ADDRESS: STREET 1: 8 THE GREEN STREET 2: SUITE # 12081 CITY: DOVER STATE: DE ZIP: 19901 10-Q 1 fhltu-20220331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-40788

Future Health ESG Corp.

(Exact name of Registrant as specified in its Charter)

Delaware

86-2305680

(State or other jurisdiction of
incorporation or organization)
8 The Green
Suite 12081
Dover, DE
(Address of principal executive offices)

(I.R.S. Employer
Identification No.)

19901

(Zip Code)

(833) 388-8734

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock and one-half of one redeemable warrant	FHLTU	The Nasdaq Stock Market LLC
Common stock par value $0.0001 per share	FHLT	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share	FHLTW	The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ⌧ NO ◻

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ⌧ NO ◻

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	◻	Smaller reporting company	⌧
Accelerated filer	◻	Emerging growth company	⌧
Non-accelerated filer	⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. YES ◻ NO ⌧

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ⌧ NO ◻

As of April 14, 2022, 25,000,000 shares of common stock, par value $0.0001 per share, were issued and outstanding.

Table of Contents

FUTURE HEALTH ESG CORP.

FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2022

TABLE OF CONTENTS


PART I – FINANCIAL INFORMATION		1
Item 1. Interim Financial Statements (Unaudited)		1
BALANCE SHEETS (Unaudited)		1
STATEMENTS OF OPERATIONS (Unaudited)		2
STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited)		3
STATEMENTS OF CASH FLOWS (Unaudited)		4
NOTES TO FINANCIAL STATEMENTS (Unaudited)		5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16
Item 3. Quantitative and Qualitative Disclosures About Market Risk		20
Item 4. Controls and Procedures		20
PART II - OTHER INFORMATION		20
Item 1. Legal Proceedings.		20
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		21
Item 3. Defaults Upon Senior Securities		21
Item 4. Mine Safety Disclosures		21
Item 5. Other Information		21
Item 6. Exhibits		22
SIGNATURES		23

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Interim Financial Statements.

FUTURE HEALTH ESG CORP.

BALANCE SHEETS


	March 31, 2022		December 31,
	(unaudited)		2021
ASSETS
Current assets:
Cash	$	1,129,587	$	1,446,482
Prepaid expenses		168,916		108,150
Total current assets		1,298,503		1,554,632
Marketable securities held in Trust Account		201,020,753		201,004,349
Other assets		54,076		74,371
Total Assets	$	202,373,332	$	202,633,352

LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION, AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable	$	—	$	20,904
Franchise tax payable		—		62,299
Accrued expenses		16,326		40,581
Total current liabilities		16,326		123,784
Deferred underwriting and advisory fees payable		9,000,000		9,000,000
Total liabilities		9,016,326		9,123,784

Commitments and Contingencies (Note 5):
Common stock subject to possible redemption, 20,000,000 shares at $10.05 per share		201,000,000		201,000,000

Stockholders' Deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding		—		—
Common stock, $0.0001 par value; 500,000,000 shares authorized; 5,000,000 shares issued and outstanding		500		500
Additional paid-in capital		—		—
Accumulated deficit		(7,643,494)		(7,490,932)
Total stockholders' deficit		(7,642,994)		(7,490,432)
Total Liabilities, Common Stock Subject to Possible Redemption, and Stockholders’ Deficit	$	202,373,332	$	202,633,352

The accompanying notes are an integral part of these unaudited financial statements.

Table of Contents

FUTURE HEALTH ESG CORP.

UNAUDITED STATEMENTS OF OPERATIONS


			For the Period From
	For the Three Months		February 25, 2021 (Inception)
	Ended March 31, 2022		Through March 31, 2021
General and administrative expenses	$	120,284	$	778
Franchise tax expense		50,000		—
Loss from operations		(170,284)		(778)
Interest income on cash balance		1,318		8
Gain on marketable securities (net), dividends and interest, held in Trust Account		16,404		—
Net Loss	$	(152,562)	$	(770)

Weighted average shares outstanding of common stock subject to possible redemption, basic and diluted		20,000,000		—
Basic and diluted net loss per share, common stock subject to possible redemption	$	(0.01)	$	—

Weighted average shares outstanding of non-redeemable common stock, basic and diluted⁽¹⁾		5,000,000		5,000,000
Basic and diluted net loss per share, non-redeemable common stock	$	(0.01)	$	(0.00)

(1)For the period from February 25, 2021 (Inception) through March 31, 2021, includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and excludes an aggregate of 750,000 founder shares forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4).

The accompanying notes are an integral part of these unaudited financial statements.

Table of Contents

FUTURE HEALTH ESG CORP.

UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ EQUITY (DEFICIT)


	For the Period from February 25, 2021 (Inception) Through March 31, 2021
	Common Stock Subject						Additional				Total
	to Possible Redemption			Common Stock			Paid-In		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Capital		Deficit		Equity
Balance as of February 25, 2021 (inception)	—	$	—	—	$	—	$	—	$	—	$	—
Issuance of common stock to Sponsor⁽¹⁾	—		—	5,750,000		575		32,758		—		33,333
Net Loss	—		—	—		—		—		(770)		(770)
Balance as of March 31, 2021 (unaudited)	—	$	—	5,750,000	$	575	$	32,758	$	(770)	$	32,563

For the Three Months Ended March 31, 2022

Common Stock Subject

Additional

Total

to Possible Redemption

Common Stock

Paid-In

Accumulated

Stockholders’

Shares

Amount

Shares

Amount

Capital

Deficit

Balance as of December 31, 2021

20,000,000

201,000,000

5,000,000

500

—

(7,490,932)

(7,490,432)

Net loss

—

(152,562)

Balance as of March 31, 2022 (unaudited)

20,000,000

201,000,000

5,000,000

500

—

(7,643,494)

(7,642,994)

(1)Includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and also includes an aggregate of 750,000 founder shares issued and outstanding at March 31, 2021 that were forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4).

The accompanying notes are an integral part of these unaudited financial statements.

Table of Contents

FUTURE HEALTH ESG CORP.

UNAUDITED STATEMENTS OF CASH FLOWS


			For the Period From
	For the Three Months			February 25, 2021 (Inception)
	Ended March 31,		Through March 31,
	2022		2021
Cash Flows from Operating Activities:
Net loss	$	(152,562)	$	(770)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on marketable securities (net), dividends and interest, held in Trust Account		(16,404)		—
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(40,471)		(179,724)
Accounts payable and accrued expenses		(107,458)		39,249
Net cash used in operating activities		(316,895)		(141,245)

Cash Flows from Financing Activities:
Advances from related party		—		132,920
Proceeds from issuance of common stock to Sponsor		—		33,333
Net cash provided by financing activities		—		166,253

Net (decrease) increase in cash		(316,895)		25,008
Cash - beginning of period		1,446,482		—
Cash - end of period	$	1,129,587	$	25,008

The accompanying notes are an integral part of these financial statements.

Table of Contents

FUTURE HEALTH ESG CORP.

NOTES TO MARCH 31, 2022 UNAUDITED FINANCIAL STATEMENTS

Note 1 — Description of Organization and Business Operations

Organization and General

Future Health ESG Corp. (the “Company”) is a blank check company incorporated in Delaware on February 25, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (the “Business Combination”). The Company is an “emerging growth company”, and as such, the Company is subject to all the risks associated with emerging growth companies.

As of March 31, 2022, the Company had not commenced any operations. All activity for the period from February 25, 2021 (inception) through March 31, 2022 relates to the Company’s formation, the initial public offering described below and, since the initial public offering, the search for a target business for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents held in the trust and operating accounts. The Company has selected December 31 as its fiscal year end.

On September 9, 2021, (the “Company”) consummated its initial public offering (the “IPO”) of 20,000,000 units (the “Units”). Each Unit consists of one share of common stock and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one share of common stock for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $200,000,000, as further described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of 7,375,000 warrants (the “Private Placement Warrants”) at a purchase price of $1.00 per Private Placement Warrant (the “Private Placement”) to Future Health ESG Associates 1, LLC (the “Sponsor”) and Cantor Fitzgerald & Co, generating gross proceeds to the Company of up to $7,375,000, as further described in Note 4.

Transaction costs amounted to $21,881,745, including $9,000,000 in deferred underwriting and advisory fees payable, $4,019,555 in upfront underwriting fees, $8,163,891 in offering costs allocated to the fair value of the common shares offered to anchor investors by certain related parties (see Note 3), and $698,299 in other offering costs related to the Initial Public Offering.

A total of $201,000,000 ($10.05 per redeemable share sold in the IPO), comprised of proceeds from the IPO and the sale of the Private Placement Warrants, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds held in the trust account that may be released to the Company to pay its taxes, if any, the funds held in the trust account will not be released from the trust account until the earliest of: (1) the completion of the Company’s initial business combination; (2) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with its initial business combination or to redeem 100% of its public shares if the Company does not complete its initial business combination within 15 months from the closing of the IPO (by December 14, 2022) or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of all of the Company’s public shares if it has not completed its initial business combination within 15 months from the closing of the IPO, subject to applicable law.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in Trust and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company only intends to complete a Business Combination if the post-transaction company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a

Table of Contents

controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”).

The Company provides the holders (the “Public Stockholders”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share, sold in the Initial Public Offering (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders are entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (anticipated to be approximately $10.05 per Public Share). The per-share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting and advisory fees the Company will pay to the underwriters (as discussed in Note 5). These Public Shares were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.”

If the Company seeks stockholder approval, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem the Public Shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) have agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the initial stockholders have agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination.

The Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company. The holders of the Founder Shares (the “initial stockholders”) have agreed not to propose an amendment to the Certificate of Incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (B) with respect to any other provision relating to stockholder’s rights or pre-initial Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

If the Company is unable to complete a Business Combination within 15 months from the closing of the Initial Public Offering (by December 14, 2022) (the “Combination Period”) and the Company’s stockholders have not amended the Certificate of Incorporation to extend such Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but no more than ten business days thereafter subject to lawfully available funds therefor, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.

The initial stockholders have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the

Table of Contents

Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting and advisory fees (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.05. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement (a “Target”), reduce the amount of funds in the Trust Account to below (i) $10.05 per Public Share or (ii) the lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of interest which may be withdrawn to pay taxes, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, our sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

COVID-19

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. Management continues to evaluate the impact of the COVID-19 outbreak on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited financial statements. The unaudited financial statements do not include any adjustments to reflect the outcome of this uncertainty.

Going Concern

On a routine basis, the Company assesses going concern considerations in accordance with ASC 205-40, “Presentation of Financial Statements - Going Concern”. As of March 31, 2022, we had $1,129,587 in our operating bank account, $1,282,177 of working capital, and $201,020,753 of securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem our common stock in connection therewith. We believe that we will have sufficient working capital and borrowing capacity to meet our needs through the earlier of the consummation of a Business Combination or one year from this filing, however, there is a risk that our liquidity may not be sufficient. The Sponsor intends, but is not obligated to, provide us with Working Capital Loans to sustain operations in the event of a liquidity deficiency.

We have until December 14, 2022 to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension is not requested by the Sponsor there will be a mandatory liquidation and subsequent dissolution of the Company. While Management expects to complete a Business Combination prior to December 14, 2022, this date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 2 — Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in annual financial

Table of Contents

statements prepared in accordance with GAAP have been or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of unaudited financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements and the reported amounts of income and expenses during the reporting period.

Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Net Loss Per Share of Common Stock

Table of Contents

The Company’s statement of operations includes a presentation of loss per share of common stock subject to possible redemption in a manner similar to the two-class method of loss per share. As of March 31, 2022 and 2021, the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. Remeasurement adjustment on redeemable common stock is not considered in the calculation because redemption value closely approximates fair value.


				For the Period From
	For the Three Months			February 25, 2021 (Inception)
	Ended March 31, 2022			Through March 31, 2021
Redeemable Common Stock
Allocation of net loss	$	(122,049)	$	—
Denominator:
Weighted average shares of redeemable common stock outstanding		20,000,000		—
Basic and Diluted Net Loss per Redeemable Common Share	$	(0.01)	$	—
Non-Redeemable Common Stock
Allocation of net loss	$	(30,512)	$	(770)
Denominator:
Weighted average shares of non-redeemable common stock outstanding⁽¹⁾		5,000,000		5,000,000
Basic and Diluted Net Loss per Non-Redeemable Common Share	$	(0.01)	$	(0.00)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of the date of this quarterly report, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Fair Value of Financial Instruments

The Company applies ASC 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:

Level 1 – Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

Table of Contents

Level 3 – Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

The Company’s marketable securities held in trust of $201,020,753 as of March 31, 2022, and $201,004,349 as of December 31, 2021 are deemed cash and cash equivalents which are considered level 1 classified. There were no transfers to and from Levels 1, 2, and 3 during the three months ended March 31, 2022, or the period from February 25, 2021 (inception) through March 31, 2021.

Offering Costs

Offering costs consist of legal, accounting, and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering and were allocated to temporary equity or stockholders' deficit upon the completion of the Initial Public Offering. Offering costs were $21,881,745. The Company complies with the requirements of the ASC 340-10-S99-1.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The Company must then present them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the Company’s warrants defined in Note 6 do not exhibit any of the above characteristics and, therefore are outside the scope of ASC 480.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The 10,000,000 Public Warrants and 7,375,000 Private Placement Warrants, excluding over-allotment, were issued in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants meet the criteria for equity treatment thereunder, each warrant will be recorded as equity. The Company, therefore, accounts for its outstanding warrants as equity-classified instruments.

Income Taxes

The Company complies with the accounting and reporting requirements of ASC, 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

There were no unrecognized tax benefits as of March 31, 2022 or December 31, 2021. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material

Table of Contents

deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The effective tax rate differs from the statutory rate of 21% for the three months ended March 31, 2022 and the period from February 25, 2021 (Inception) through March 31, 2021 due to the valuation allowance recorded against the deferred tax benefit relating to the Company’s net operating losses.

Recent Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020- 06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years beginning after December 15, 2021 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company early adopted ASU 2020-06 effective upon inception on February 25, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s unaudited financial statements.

The Company’s management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the accompanying unaudited financial statements.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $1,129,587 and $1,446,482 in cash (and no cash equivalents) as of March 31, 2022 and December 31, 2021, respectively.

Marketable Securities Held in Trust Account

As of the date of this quarterly report, the assets held in the Trust Account were held in investments in money market funds.

Common Stock Subject to Possible Redemption

The Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including shares of common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ deficit. The Company’s common stock represented by Public Shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, all common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, the Company recognized the remeasurement of initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital, to the extent available, and accumulated deficit.

Note 3 — Public Offering

Pursuant to the Initial Public Offering, the Company sold 20,000,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one share of common stock and one-half of one Public Warrant. Each whole Public Warrant entitles the holder to purchase one share of common stock at an exercise price of $11.50 per share.

Table of Contents

Twelve anchor investors, none of whom is affiliated with any member of our management team, purchased an aggregate of 19,480,000 of the units sold in the Initial Public Offering. Further, each such anchor investor purchased a pro-rata portion of 1,229,798 Founder Shares (defined below) from MB Equity, LLC, an affiliate of Bradley Bostic, the Company’s Chief Executive Officer and a director, and Travis Morgan, the Company’s Chief Financial Officer, and a director, at a price of $0.0058 per share.

The Company has determined the excess fair value of the Founder Shares sold to the anchor investors to be $8,163,891. To estimate the fair value, management considered the probability and timing of IPO completion, business combination completion, and an appropriate discount for lack of marketability, all Level 3 Inputs under ASC 820. The excess of the fair value of the Founder Shares was determined to be an offering cost in accordance with Staff Accounting Bulletin Topic 5A and was charged to common stock subject to possible redemption upon completion of the Initial Public Offering. In accordance with Staff Accounting Bulletin Topic 5T, a capital contribution from the founders was recorded in additional paid-in capital.

The underwriter did not exercise their overallotment option to purchase an additional 3,000,000 private warrants within the 45 day limit. Management determined the fair value of this option to be immaterial, therefore, the unaudited financial statements do not include any adjustments relating to the expiration of the overallotment option.

Note 4 — Related Party Transactions

Founder Shares

On March 3, 2021, entities affiliated with our executive officers acquired 4,312,500 founder shares, up to 562,500 of which were subject to forfeiture (the “Founder Shares”), for an aggregate purchase price of $25,000. Prior to the initial investment in the Company of $25,000 by our founders, we had no assets, tangible, or intangible. On July 16, 2021, the Company issued an additional 1,437,500 Founder Shares to the Sponsor, up to 187,500 of which were subject to forfeiture, in exchange for $8,333 in cash. All shares and associated amounts have been retroactively restated in the period from February 25, 2021 (Inception) through March 31, 2021 to reflect the additional founder shares. A total of 750,000 founder shares were forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021.

The Company’s initial stockholders, officers and directors have agreed not to transfer, assign or sell any Founder Shares held by them until the earlier to occur of: (1) one year after the completion of the initial Business Combination; and (2) subsequent to the initial Business Combination, (x) the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the public stockholders having the right to exchange their shares of common stock for cash, securities or other property or (y) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at the initial Business Combination. Any permitted transferees would be subject to the same restrictions and other agreements of the initial stockholders with respect to any Founder Shares (the “Lock-up”).

On March 23, 2021, the Sponsor sold an aggregate of 38,814 founder shares to directors at a price of $0.0058 per share. The Company determined the excess fair value over consideration paid for the founder shares transferred to be $46,288 as of the grant date. To estimate the fair value, management considered the probability and timing of IPO completion, business combination completion, and an appropriate discount for lack of marketability, all Level 3 Inputs under ASC 820.

The sale of Founder Shares to members of the Company’s board of directors is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity classified awards is measured at fair value upon the grant date. The Founder Shares were effectively sold or transferred subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. A business combination is not probable until it is completed. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founder Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares. As of March 31, 2022, a business combination had not yet been completed, therefore, no stock-based compensation expense has been recognized.

Table of Contents

Related Party Loans

Future Health ESG Associates 1, LLC agreed to loan the Company up to $250,000 to cover expenses related to the Initial Public Offering pursuant to two promissory notes dated March 4, 2021 and August 24, 2021. These notes are non-interest bearing and payable on the earlier of March 31, 2022 and the closing of the Initial Public Offering. The Company borrowed a total of $250,000 prior to the Initial Public Offering, and subsequently repaid the full balance after the closing of the Initial Public Offering. There was no outstanding balance on the notes as of the date of this quarterly report.

Private Placement Warrants

On September 9, 2021, the Company entered into Private Placement Warrants Purchase Agreements for the private sale (the “Private Placement”) of 7,375,000 warrants to its initial stockholders and Cantor Fitzgerald & Co (such warrants, collectively, the “Private Placement Warrants”), at a purchase price of $1.00 per Private Placement Warrant, for gross proceeds to the Company of up to $7,375,000. Each whole warrant entitles the holder thereof to purchase one share of Common Stock for $11.50 per share, subject to adjustment. No underwriting discounts or commissions were paid with respect to the Private Placement. The Private Placement was conducted as a non-public transaction pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 (as amended, the “Securities Act”).

The purchasers of the Private Placement Warrants have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants (except to permitted transferees) until 30 days after the completion of the initial Business Combination.

Working Capital Loans

In order to finance transaction costs in connection with a Business Combination, the Sponsor, or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender’s discretion, up to $2,000,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. To date, the Company had no borrowings under the Working Capital Loans.

Note 5 — Commitments and Contingencies

Registration Rights

The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any (and any shares of common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans), are entitled to registration rights pursuant to a registration rights agreement. These holders are entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that we will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement and Advisory Fees

The Company paid an underwriting discount of 2.0% of the per Unit offering price to Cantor Fitzgerald & Co at the closing of the Initial Public Offering, with an additional fee of 4.5% of the gross offering proceeds payable only upon the Company’s completion of

Table of Contents

its Initial Business Combination, of which $8,700,000 will be paid to Cantor Fitzgerald & Co and $300,000 will be paid to Roth Capital Partners, LLC, an independent financial advisor to the Company.

The Company has entered into capital markets advisory agreements with multiple advisors pursuant to which fees will be paid in an aggregate amount of up to 2% of the cash retained from the trust account (net of redemptions) plus any gross proceeds raised in a financing relating to an Initial Business Combination. The capital markets advisory fees are contingent on both the consummation and the specific terms of an Initial Business Combination, neither of which can be reasonably predicted at this time. Accordingly, no accrual has been made for these arrangements in the unaudited financial statements.

Note 6 — Stockholders’ Deficit

Preferred Stock — The Company is authorized to issue 5,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s Board of Directors. As of the date of this quarterly report, there were no shares of preferred stock issued or outstanding.

Common Stock — The Company is authorized to issue 500,000,000 shares of common stock with a par value of $0.0001 per share. As of December 31, 2021, there were 25,000,000 shares of common stock issued and outstanding. Up to 20,000,000 of outstanding common stock shares were issued in conjunction with the IPO and are redeemable at a price of $10.05 per share. Redeemable common stock shares are classified as temporary equity and are excluded from total stockholders' deficit. The remaining 5,000,000 outstanding shares of common stock are non-redeemable Founder Shares and are included in total stockholders’ deficit.

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants were issued upon separation of the Units (which occurred on December 9, 2021) and only whole Public Warrants will trade. The Public Warrants will become exercisable 30 days after the completion of a Business Combination. The Company has agreed that as soon as practicable after the closing of its initial Business Combination, the Company will use its best efforts to file with the SEC and have an effective registration statement covering the shares of common stock issuable upon exercise of the warrants and will use its best efforts to cause the same to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed. If, at any time beginning on the 61st business day after the closing of our initial business combination, the shares of common stock issuable upon exercise of the public warrants are not covered by an effective registration statement, the holders of the public warrants will be entitled to exercise such warrants on a cashless basis. However, no public warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

Both Public and Private Warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if, in connection with an initial business combination, (x) the Company issues additional shares of common stock or equity-linked securities at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price as determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the consummation of such Business Combination (net of redemptions) and (z) the volume weighted average trading price of common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.

The Private Placement Warrants are identical to the Public Warrants, except that (i) they will not be redeemable by the Company, (ii) they may not, subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of the initial Business Combination, (iii) they may be exercised by the holders on a cashless basis, (iv) they are subject to registration rights and (v) Cantor Fitzgerald & Co. has agreed that it shall have the right to exercise the Private Placement Warrants until, and shall forfeit to us for cancellation any Private Placement Warrants held by it on, the date that is five years after the effective date of the registration statement of which this prospectus forms a part in accordance with FINRA Rule 5110(g)(8)(A).

Table of Contents

Redemption of public warrants: Once the public warrants become exercisable, the Company may redeem the outstanding public warrants for cash (except as described herein with respect to the Private Placement Warrants):

●

In whole and not in part;

●

At a price of $0.01 per warrant;

●

Upon a minimum of 30 days’ prior written notice of redemption; and

●

if, and only if, the last reported sale price of our common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders.

The Company will not redeem the warrants for cash as described above unless an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period. Any such exercise would not be on a cashless basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised.

In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

Note 7 — Subsequent Events

Management has evaluated the impact of subsequent events that occurred after the balance sheet date up to the date the unaudited financial statements were issued and has not identified any subsequent events that would have required adjustment or disclosure in the unaudited financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company," "Future Health,” “our,” “us” or “we” refer to Future Health ESG Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those set forth under “Risk Factors”.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance, or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Form S-1 filed with the U.S. Securities and Exchange Commission (the “SEC”), and declared effective on September 9, 2021, and the Company's annual report Form 10-K filed with the SEC on March 28, 2022. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

Future Health is a blank check company incorporated in Delaware on February 25, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (the “Business Combination”). We intend to effectuate our business combination using cash from the proceeds of our initial public offering and the sale of the private warrants, our capital stock, debt, or a combination of cash, stock, and debt. The Company is an “emerging growth company”, and as such, the Company is subject to all the risks associated with emerging growth companies.

Results of Operations

As of March 31, 2022, the Company had not commenced any operations. All activity for the period from February 25, 2021 (inception) through March 31, 2022 relates to the Company’s formation and initial public offering described below and, since the initial public offering, the search for a target business for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO (as defined below). The Company has selected December 31 as its fiscal year end.

On September 9, 2021, the Company consummated its initial public offering (the “IPO”) of 20,000,000 units (the “Units”). Each Unit consists of one share of common stock and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one share of common stock for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $200,000,000.

Table of Contents

Simultaneously with the closing of the IPO, the Company completed the private sale of 7,375,000 warrants (the “Private Placement Warrants”) at a purchase price of $1.00 per Private Placement Warrant (the “Private Placement”), to Future Health ESG Associates 1, LLC (the “Sponsor”) and Cantor Fitzgerald & Co, generating gross proceeds to the Company of $7,375,000.

From the proceeds of the IPO and the Private Placement, an aggregate of $201,000,000 was placed into a trust account for the benefit of the Company’s public stockholders to fund redemptions of the shares of common stock held by the Company’s public stockholders (the “Trust Account”), to be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the requirements of Rule 2(a)(7) of the Investment Company Act, until the earlier of (i) the consummation of a business combination or (ii) the distribution of the Trust Account.

Transaction costs amounted to $21,855,745, including $9,000,000 in deferred underwriting and advisory fees payable, $4,019,555 in upfront underwriting fees, $8,163,891 in offering costs allocated to anchor investors, and $698,299 in other offering costs related to the IPO.

For the three months ended March 31, 2022, we incurred a net loss of $152,562, which consisted of operating costs of $170,284, partially offset by interest income on our cash balance of $1,318 and net gains on marketable securities held in our operating and trust accounts of $16,404.

For the period from February 25, 2021 (inception) through March 31, 2021, we incurred a net loss of $770, which consisted of general and administrative expenses of $778, partially offset by interest income on our cash balance of $8.

Liquidity and Capital Resources

On September 14, 2021, the Company consummated the IPO of 20,000,000 units. Each Unit consists of one share of common stock and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one share of common stock for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $200,000,000. Simultaneously with the closing of the IPO, the Company completed the Private Placement of 7,375,000 Private Placement Warrants at a purchase price of $1.00 per Private Placement Warrant to the Sponsor and Cantor Fitzgerald & Co, generating gross proceeds to the Company of $7,375,000.

Following the IPO and the sale of the Private Placement Warrants, $201,000,000 ($10.05 per redeemable share sold in the IPO) was placed in the Trust Account. We incurred $21,881,745 in transaction costs, including $9,000,000 in deferred underwriting and advisory fees payable, $4,019,555 in upfront underwriting fees, $8,163,891 in offering costs allocated to the fair value of the common shares sold to anchor investors by certain related parties, and $698,299 of other offering costs related to the IPO.

For the three months ended March 31, 2022, cash used in operating activities was $316,895, comprised of a net loss of $152,562, gain on marketable securities (net), dividends and interest held in Trust Account of $16,404, and $147,929 in cash used by changes in operating assets and liabilities.

For the period from February 25, 2021 (inception) through March 31, 2022, cash used in operating activities was $141,245, comprised of a net loss of $770 and $140,475 in cash used by changes in operating assets and liabilities. Cash provided by financing activities was $166,253, comprised of $33,333 in proceeds from issuance of common stock to the Sponsor, and $132,920 in advances from the Sponsor.

As of March 31, 2022, we had cash and marketable securities held in the Trust Account of $201,020,753. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less deferred underwriting and advisory fees payable and income taxes payable), to complete our Business Combination. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

Table of Contents

As of March 31, 2022, we had cash of $1,129,587. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete a Business Combination.

Future Health ESG Associates 1, LLC loaned us $250,000 to cover expenses related to the IPO pursuant to two promissory notes dated March 4, 2021 and August 24, 2021. At March 31, 2021, $132,920 had been drawn against the notes. These notes were non-interest bearing and repaid in full after the closing of the IPO on September 14, 2021.

In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, our Sponsor, or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete a Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. In the event that a Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment. Up to $2,000,000 of such loans may be convertible into warrants, at a price of $1.00 per warrant, at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of March 31, 2022, no amount had been borrowed from the Sponsor, officers, or directors.

We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence, and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our public shares upon consummation of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our Business Combination. If we are unable to complete our Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following our Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

Going Concern

On a routine basis, we assess going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, “Presentation of Financial Statements - Going Concern”. As of March 31, 2022, we had $1,129,587 in our operating bank account, $1,282,177 of working capital, and $201,020,753 of securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem our common stock in connection therewith. We believe that we will have sufficient working capital and borrowing capacity to meet our needs through the earlier of the consummation of a Business Combination or one year from this filing, however, there is a risk that our liquidity may not be sufficient. The Sponsor intends, but is not obligated to, provide us with Working Capital Loans to sustain operations in the event of a liquidity deficiency.

Off-Balance Sheet Arrangements

We have no obligations, assets, or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2022. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Table of Contents

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than described below.

The underwriter of the IPO was paid $4,019,555 in underwriting discount and expense reimbursement upon the closing of the IPO. An additional $9,000,000 of deferred underwriting fees will be due to the underwriter only upon the closing of an Initial Business Combination. Included in this amount is a financial advisory fee of $300,000 that will be payable to Roth Capital Partners, LLC only upon the closing of an Initial Business Combination.

Critical Accounting Estimates and Policies

The preparation of unaudited financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. The Company's management has reviewed all estimates used in the preparation of the unaudited financial statements and has determined that none reflect both a significant level of estimation uncertainty and a reasonable likelihood of material impact on the Company's financial condition or results of operations.

Common Stock Subject to Possible Redemption

The Company accounts for its common Stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Shares of common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including shares of common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ deficit. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of March 31, 2022 and December 31, 2021, all common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, the Company recognized the remeasurement from initial book value to redemption value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital, to the extent available, and accumulated deficit.

Net Loss per Share of Common Stock

Earnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares issued and outstanding during the period. Earnings and losses are allocated to redeemable and non-redeemable common stock based on weighted-average shares outstanding. The Company has not considered the effect of warrants sold in the IPO and private placement to purchase common stock in the calculation of diluted income (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events. The Company’s statement of operations includes a presentation of income (loss) per share of common stock subject to possible redemption in a manner similar to the two-class method of income (loss) per share. As of March 31, 2022 and 2021, the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. Remeasurement adjustment on redeemable common stock is not considered in the calculation because redemption value closely approximates fair value.

Table of Contents

Recent Accounting Standards

In August 2020, the FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020- 06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years beginning after December 15, 2021, and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company early adopted ASU 2020-06 effective upon inception on February 25, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s unaudited financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As of the date of this quarterly report, we were not subject to any material market or interest rate risk. Following the consummation of our initial public offering, the net proceeds of our initial public offering, including amounts in the trust account, have been invested in U.S. government treasury bills, notes or bonds with a maturity of 185 days or less or in certain money market funds that invest solely in U.S. treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended March 31, 2022, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that during the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level and, accordingly, provided reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended March 31, 2022, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

We are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us or any of our officers or directors in their corporate capacity.

Table of Contents

Item 1A. Risk Factors.

As of the date of this quarterly report, there have been no material changes with respect to those risk factors previously disclosed in our Registration Statement filed with the SEC and our annual report on Form 10-K filed with the SEC. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

The following exhibits are filed as part of, or incorporated by reference into, this quarterly report on Form 10-Q.


Exhibit Number		Description of Document
31.1*		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*		Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

* Furnished herewith.

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	Future Health ESG Corp.

Date: April 14, 2022	By:	/s/ Bradley A. Bostic
	Name:	Bradley A. Bostic
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Date: April 14, 2022	By:	/s/ Travis A. Morgan
	Name:	Travis A. Morgan
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 fhltu-20220331xex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bradley A. Bostic, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 of Future Health ESG Corp. (the “Company”).

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the entity, particularly during the period in which this report is being prepared;

(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: April 14, 2022	By:	/s/Bradley A. Bostic
		Name: Bradley A. Bostic
		Title: Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 fhltu-20220331xex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Travis A. Morgan, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 of Future Health ESG Corp. (the “Company”).

3.	Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 14, 2022	By:	/s/Travis A. Morgan
		Name: Travis A. Morgan
		Title: Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-32.1 4 fhltu-20220331xex32d1.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Future Health ESG Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bradley A. Bostic, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: April 14, 2022	By:	/s/ Bradley A. Bostic
		Name: Bradley A. Bostic
		Title: Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 fhltu-20220331xex32d2.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Future Health ESG Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Travis A. Morgan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: April 14, 2022	By:	/s/Travis A. Morgan
		Name: Travis A. Morgan
		Title: Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-101.SCH 6 fhltu-20220331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - UNAUDITED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - UNAUDITED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - UNAUDITED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S EQUITY (DEFICIT) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Description of Organization and Business Operations (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies - Basic and diluted net loss per common share (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Related Party Transactions - Founder Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Related Party Transactions - Related Party Loans (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Related Party Transactions - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stockholders' Deficit - Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stockholders' Deficit - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Stockholders' Deficit - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Description of Organization and Business Operations link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Public Offering link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 fhltu-20220331_cal.xml EX-101.CAL EX-101.DEF 8 fhltu-20220331_def.xml EX-101.DEF EX-101.LAB 9 fhltu-20220331_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Information pertaining to Unit each consisting of one class common stock . Unit Each Consisting Of One Class Common Stock And One Third Redeemable Warrant Common stock Information pertaining to redeemable warrants exercisable for class common stock Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 Document Information [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag BALANCE SHEETS Statement [Table] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash held outside the Trust Account Cash Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Marketable securities held in Trust Account Marketable securities held in Trust Account Other Assets, Noncurrent Other assets Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION, AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Income Taxes, Current Franchise tax payable Accrued Liabilities, Current Accrued expenses Liabilities, Current Total current liabilities Amount of deferred underwriting and advisory fee payable classified as noncurrent. Deferred Underwriting and Advisory Fees Payable, Noncurrent Deferred underwriting and advisory fees payable Liabilities Total liabilities Commitments and Contingencies Commitments and Contingencies (Note 5): Temporary Equity, Carrying Amount, Attributable to Parent Common stock subject to possible redemption, 20,000,000 shares at $10.05 per share Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Deficit: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding Common Stock, Value, Issued Common stock, $0.0001 par value; 500,000,000 shares authorized; 5,000,000 shares issued and outstanding Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the end Balance at the beginning Total stockholders' deficit Liabilities and Equity Total Liabilities, Common Stock Subject to Possible Redemption, and Stockholders' Deficit Classification of common stock representing shares subject to possible redemption. Common stock subject to possible redemption Sale of Stock [Axis] Sale of Stock [Domain] Over-allotment option Temporary equity, shares outstanding Class A common stock subject to possible redemption, outstanding (in shares) Common shares, shares subject to possible redemption Temporary Equity, Redemption Price Per Share Common shares, redemption value per share | $ / shares Preferred Stock, Par or Stated Value Per Share Preferred stock, par value, (per share) Preferred stock, par value, (per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred shares, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred shares, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred shares, shares outstanding Common Stock, Par or Stated Value Per Share Common shares, par value, (per share) Common shares, par value (in dollars per share) Common Stock, Shares Authorized Common shares, shares authorized Common shares, shares authorized (in shares) Common Stock, Shares, Issued Common shares, shares issued Common Stock, Shares, Outstanding Common shares, shares outstanding Represents the maximum number of common stock shares subject to forfeiture. Maximum Common Stock Shares Subject To Forfeiture Maximum shares subject to forfeiture UNAUDITED STATEMENTS OF OPERATIONS Classification of common stock representing ownership interest in a corporation. Ordinary Shares [Member] Common Stock Classification of common stock representing common stock not subject to possible redemption. Common stock not subject to possible redemption General and administrative expense General and administrative expenses Amount of franchise tax expense incurred during the period. Franchise Tax Expense Franchise tax expense Operating Income (Loss) Loss from operations Interest income Interest income on cash balance Gain (Loss) on Investments Gain on marketable securities (net), dividends and interest, held in Trust Account Gain on marketable securities (net), dividends and interest, held in Trust Account Net Income (Loss) Attributable to Parent Net Loss Net loss Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding, basic Weighted Average Number of Shares Outstanding, Diluted Weighted average shares outstanding, diluted Earnings Per Share, Basic and Diluted Basic net income per share Income/(Loss) earning per share, basic Earnings Per Share, Diluted Diluted net income per share Income/(Loss) earning per share, diluted Represents the information pertaining to founder. Founder Shares Founder Shares Stock Issued During Period, Shares, New Issues Issuance of common stock to Sponsor (in shares) Number of shares issued Amount of cash exchange. Cash Exchange Cash exchange UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT) Equity Components [Axis] Equity Component [Domain] Additional Paid-In Capital Accumulated Deficit Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, Issued Balance at the end (in shares) Balance at the beginning (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock to Sponsor Aggregate purchase price UNAUDITED STATEMENTS OF CASH FLOWS Related Party Transaction [Axis] Related Party Transaction [Domain] This member stands for related party loans. Related Party Loans Cash Flows from Operating Activities: Net loss Net loss Adjustments to reconcile net loss to net cash used in operating activities: Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash Flows from Financing Activities: Proceeds from Related Party Debt Amount borrowed Advances from related party Proceeds from Issuance of Common Stock Proceeds from issuance of common stock to Sponsor Cash from issuance of shares Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net (decrease) increase in cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash - end of period Cash - beginning of period Description of Organization and Business Operations DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK] Description of Organization and Business Operations Summary of Significant Accounting Policies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [TEXT BLOCK] Summary of Significant Accounting Policies No definition available. Public Offering The entire disclosure on information about initial public offering. Initial Public Offering [Text Block] Public Offering Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Deficit Stockholders' Equity Note Disclosure [Text Block] Stockholders' Deficit Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Represents the accounting policy on Emerging Growth Company. Emerging Growth Company [Policy Text Block] Emerging Growth Company Use of Estimates, Policy [Policy Text Block] Use of Estimates Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share of Common Stock Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Deferred Offering Costs Offering Costs The disclosure of accounting policy for warrants. Warrants, Policy [Policy Text Block] Warrants Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents The disclosure of accounting policy for assets held in trust. Assets Held In Trust Account, Policy [Policy Text Block] Marketable Securities Held in Trust Account The disclosure of accounting policy for temporary equity. Temporary Equity, Policy [Policy Text Block] Common Stock Subject to Possible Redemption Reconciliation of Net Loss per Common Share Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Initial Public Offering Private Placement Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Warrants Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full. Private Placement Warrants Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment. Public Warrants Subsidiary, Sale of Stock [Line Items] Number of new units issued during the period. Units Issued During Period, Shares, New Issues Number of units issued Represents the number of shares in a unit. Number of Shares Issued Per Unit Number of shares in a unit Represents the number of warrants in a unit. Number of Warrants Issued Per Unit Number of warrants in a unit Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares issuable per warrant Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Purchase price, per unit Proceeds from issuance initial public offering Proceeds from issuance initial public offering US Amount to be paid per share that is classified as redemption stock by holder only in the event of a change in control of the issuer. Redeemable Price Per Share Redeemable per share Class of Warrant or Right, Number of Securities Called by Warrants or Rights Sale of Private Placement Warrants (in shares) Number of warrants issued Price per share or per unit of warrants or rights outstanding. Class of Warrant or Right, Price of Warrants or Rights Price of warrant Proceeds from Issuance of Warrants Proceeds from sale of Private Placement Warrants Represents the amount of transaction costs incurred. Transaction Costs Transaction Costs Represents the amount of offering fees incurred and paid for underwriters. Sale of Stock, Underwriting fees Underwriting fees Represents the amount of offering costs incurred. Sale of Stock, Offering Costs Offering costs Represents the amount of other offering costs incurred. Sale of Stock, Other Offering Costs Other offering costs Proceeds from Issuance or Sale of Equity Proceeds from IPO and Private Placement Warrants Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period. Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent) Threshold period from closing of public offering entity is obligated to complete Business Combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Threshold Period from Closing of Public Offering Entity is Obligated to Complete Business Combination Threshold period from closing of public offering entity is obligated to complete Business Combination Threshold Minimum Aggregate Fair Market Value as Percentage Of Assets Held in Trust Account Threshold minimum aggregate fair market value as percentage of assets held in trust account Threshold Percentage of Outstanding Voting Securities of Target to be Acquired by Post Transaction Company to Complete Business Combination Threshold percentage of outstanding voting securities of target to be acquired by post transaction company to complete business combination Amount refers to stock price per unit Stock Price Per Unit Threshold Percentage of Public Shares Subject to Redemption Without Company's Prior Written Consent Threshold Business Days for Redemption Of Public Shares Threshold business days for redemption of public shares The maximum amount permitted to be paid for dissolution expenses if a business combination is not completed within the specified period. Maximum Allowed Dissolution Expenses Amount of operating bank accounts. Operating Bank Accounts Operating bank accounts Amount of securities held in the Trust Account. Securities Held In Trust Account Securities held in Trust Account Amount represents the information about the working capital. Working Capital Cash Cash Equivalents, at Carrying Value Cash equivalents Cash, FDIC Insured Amount Cash FDIC Insured Amount Marketable Securities, Current Marketable securities held in trust Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Pre-Tax Book Loss (in percent) Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized tax benefits accrued for interest and penalties Unrecognized Tax Benefits Unrecognized tax benefits EX-101.PRE 10 fhltu-20220331_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2022	Apr. 14, 2022
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Entity File Number	001-40788
Entity Registrant Name	Future Health ESG Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-2305680
Entity Address, Address Line One	8 The Green
Entity Address, Address Line Two	Suite 12081
Entity Address, City or Town	Dover
Entity Address State Or Province	DE
Entity Address, Postal Zip Code	19901
City Area Code	833
Local Phone Number	388-8734
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		25,000,000
Entity Central Index Key	0001851182
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Unit Each Consisting Of One Class Common Stock And One Third Redeemable Warrant
Document Information [Line Items]
Title of 12(b) Security	Units, each consisting of one share of common stock and one-half of one redeemable warrant
Trading Symbol	FHLTU
Security Exchange Name	NASDAQ
Common stock
Document Information [Line Items]
Title of 12(b) Security	Common stock par value $0.0001 per share
Trading Symbol	FHLT
Security Exchange Name	NASDAQ
Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50
Document Information [Line Items]
Title of 12(b) Security	Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share
Trading Symbol	FHLTW
Security Exchange Name	NASDAQ

XML 12 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 1,129,587	$ 1,446,482
Prepaid expenses	168,916	108,150
Total current assets	1,298,503	1,554,632
Marketable securities held in Trust Account	201,020,753	201,004,349
Other assets	54,076	74,371
Total Assets	202,373,332	202,633,352
Current liabilities:
Accounts payable		20,904
Franchise tax payable		62,299
Accrued expenses	16,326	40,581
Total current liabilities	16,326	123,784
Deferred underwriting and advisory fees payable	9,000,000	9,000,000
Total liabilities	9,016,326	9,123,784
Commitments and Contingencies (Note 5):
Common stock subject to possible redemption, 20,000,000 shares at $10.05 per share	201,000,000	201,000,000
Stockholders' Deficit:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding
Common stock, $0.0001 par value; 500,000,000 shares authorized; 5,000,000 shares issued and outstanding	500	500
Additional paid-in capital	0	0
Accumulated deficit	(7,643,494)	(7,490,932)
Total stockholders' deficit	(7,642,994)	(7,490,432)
Total Liabilities, Common Stock Subject to Possible Redemption, and Stockholders' Deficit	$ 202,373,332	$ 202,633,352

XML 13 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common shares, shares subject to possible redemption	20,000,000	20,000,000
Common shares, redemption value per share \| $ / shares	$ 10.05	$ 10.05
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common shares, par value, (per share)	$ 0.0001	$ 0.0001
Common shares, shares authorized	500,000,000	500,000,000
Common shares, shares issued	5,000,000	5,000,000
Common shares, shares outstanding	5,000,000	5,000,000
Common stock subject to possible redemption
Common shares, shares subject to possible redemption	20,000,000
Common shares, redemption value per share \| $ / shares	$ 10.05

XML 14 R4.htm IDEA: XBRL DOCUMENT

UNAUDITED STATEMENTS OF OPERATIONS - USD ($)

1 Months Ended

3 Months Ended

Mar. 31, 2021

Mar. 31, 2022

General and administrative expenses

$ 778

$ 120,284

Franchise tax expense

50,000

Loss from operations

(778)

(170,284)

Interest income on cash balance

1,318

Gain on marketable securities (net), dividends and interest, held in Trust Account

16,404

Net Loss

$ (770)

$ (152,562)

Common stock subject to possible redemption

Weighted average shares outstanding, basic

20,000,000

Weighted average shares outstanding, diluted

20,000,000

Basic net income per share

$ (0.01)

Diluted net income per share

$ (0.01)

Common stock not subject to possible redemption

Weighted average shares outstanding, basic

^[1]

5,000,000

Weighted average shares outstanding, diluted

^[1]

5,000,000

Basic net income per share

$ 0.00

$ (0.01)

Diluted net income per share

$ 0.00

$ (0.01)

[1]

For the period from February 25, 2021 (Inception) through March 31, 2021, includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and excludes an aggregate of 750,000 founder shares forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4).

XML 15 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED STATEMENTS OF OPERATIONS (Parenthetical) - Founder Shares	1 Months Ended
	Mar. 31, 2021 USD ($) shares
Number of shares issued	1,427,500
Cash exchange \| $	$ 8,333
Over-allotment option
Maximum shares subject to forfeiture	750,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)

Common stock subject to possible redemption

Common stock

Additional Paid-In Capital

Accumulated Deficit

Total

Balance at the beginning at Feb. 24, 2021

$ 0

Balance at the beginning (in shares) at Feb. 24, 2021

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of common stock to Sponsor

^[1]

$ 575

32,758

33,333

Issuance of common stock to Sponsor (in shares)

^[1]

5,750,000

Net loss

(770)

Balance at the end at Mar. 31, 2021

$ 575

$ 32,758

(770)

32,563

Balance at the end (in shares) at Mar. 31, 2021

5,750,000

Balance at the beginning at Dec. 31, 2021

$ 201,000,000

$ 500

(7,490,932)

(7,490,432)

Balance at the beginning (in shares) at Dec. 31, 2021

20,000,000

5,000,000

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss

(152,562)

Balance at the end at Mar. 31, 2022

$ 201,000,000

$ 500

$ (7,643,494)

$ (7,642,994)

Balance at the end (in shares) at Mar. 31, 2022

20,000,000

5,000,000

[1]

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 17 R7.htm IDEA: XBRL DOCUMENT

UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S EQUITY (DEFICIT) (Parenthetical) - Founder Shares	1 Months Ended
	Mar. 31, 2021 USD ($) shares
Number of shares issued	1,427,500
Cash exchange \| $	$ 8,333
Over-allotment option
Maximum shares subject to forfeiture	750,000

XML 18 R8.htm IDEA: XBRL DOCUMENT

UNAUDITED STATEMENTS OF CASH FLOWS - USD ($)	1 Months Ended	3 Months Ended
UNAUDITED STATEMENTS OF CASH FLOWS - USD ($)	Mar. 31, 2021	Mar. 31, 2022
Cash Flows from Operating Activities:
Net loss	$ (770)	$ (152,562)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on marketable securities (net), dividends and interest, held in Trust Account		(16,404)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(179,724)	(40,471)
Accounts payable and accrued expenses	39,249	(107,458)
Net cash used in operating activities	(141,245)	(316,895)
Cash Flows from Financing Activities:
Advances from related party	132,920
Proceeds from issuance of common stock to Sponsor	33,333
Net cash provided by financing activities	166,253
Net (decrease) increase in cash	25,008	(316,895)
Cash - beginning of period		1,446,482
Cash - end of period	$ 25,008	1,129,587
Related Party Loans
Cash Flows from Financing Activities:
Advances from related party		$ 250,000

XML 19 R9.htm IDEA: XBRL DOCUMENT

Description of Organization and Business Operations

3 Months Ended

Mar. 31, 2022

Description of Organization and Business Operations

Description of Organization and Business Operations

Note 1 — Description of Organization and Business Operations

Organization and General

controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”).

COVID-19

Going Concern

XML 20 R10.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2022

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2 — Summary of Significant Accounting Policies

Basis of Presentation

Emerging Growth Company

Use of Estimates

Net Loss Per Share of Common Stock


				For the Period From
	For the Three Months			February 25, 2021 (Inception)
	Ended March 31, 2022			Through March 31, 2021
Redeemable Common Stock
Allocation of net loss	$	(122,049)	$	—
Denominator:
Weighted average shares of redeemable common stock outstanding		20,000,000		—
Basic and Diluted Net Loss per Redeemable Common Share	$	(0.01)	$	—
Non-Redeemable Common Stock
Allocation of net loss	$	(30,512)	$	(770)
Denominator:
Weighted average shares of non-redeemable common stock outstanding⁽¹⁾		5,000,000		5,000,000
Basic and Diluted Net Loss per Non-Redeemable Common Share	$	(0.01)	$	(0.00)

Concentration of Credit Risk

Fair Value of Financial Instruments

Level 3 – Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

Offering Costs

Warrants

Income Taxes

Recent Accounting Pronouncements

Cash and Cash Equivalents

Marketable Securities Held in Trust Account

As of the date of this quarterly report, the assets held in the Trust Account were held in investments in money market funds.

Common Stock Subject to Possible Redemption

XML 21 R11.htm IDEA: XBRL DOCUMENT

Public Offering

3 Months Ended

Mar. 31, 2022

Public Offering

Public Offering

Note 3 — Public Offering

XML 22 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Mar. 31, 2022

Related Party Transactions

Related Party Transactions

Note 4 — Related Party Transactions

Founder Shares

Related Party Loans

Private Placement Warrants

Working Capital Loans

XML 23 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies.

Commitments and Contingencies

Note 5 — Commitments and Contingencies

Registration Rights

Underwriting Agreement and Advisory Fees

its Initial Business Combination, of which $8,700,000 will be paid to Cantor Fitzgerald & Co and $300,000 will be paid to Roth Capital Partners, LLC, an independent financial advisor to the Company.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

3 Months Ended

Mar. 31, 2022

Stockholders' Deficit

Stockholders' Deficit

Note 6 — Stockholders’ Deficit

●

In whole and not in part;

●

At a price of $0.01 per warrant;

●

Upon a minimum of 30 days’ prior written notice of redemption; and

●

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Mar. 31, 2022

Subsequent Events

Subsequent Events

Note 7 — Subsequent Events

XML 26 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2022

Summary of Significant Accounting Policies

Basis of Presentation

Emerging Growth Company

Use of Estimates

Net Loss Per Share of Common Stock


				For the Period From
	For the Three Months			February 25, 2021 (Inception)
	Ended March 31, 2022			Through March 31, 2021
Redeemable Common Stock
Allocation of net loss	$	(122,049)	$	—
Denominator:
Weighted average shares of redeemable common stock outstanding		20,000,000		—
Basic and Diluted Net Loss per Redeemable Common Share	$	(0.01)	$	—
Non-Redeemable Common Stock
Allocation of net loss	$	(30,512)	$	(770)
Denominator:
Weighted average shares of non-redeemable common stock outstanding⁽¹⁾		5,000,000		5,000,000
Basic and Diluted Net Loss per Non-Redeemable Common Share	$	(0.01)	$	(0.00)

Concentration of Credit Risk

Concentration of Credit Risk

Fair Value of Financial Instruments

Level 3 – Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

Offering Costs

Offering Costs

Warrants

Warrants

Income Taxes

Recent Accounting Pronouncements

Cash and Cash Equivalents

Marketable Securities Held in Trust Account

As of the date of this quarterly report, the assets held in the Trust Account were held in investments in money market funds.

Common Stock Subject to Possible Redemption

XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2022

Summary of Significant Accounting Policies

Reconciliation of Net Loss per Common Share


				For the Period From
	For the Three Months			February 25, 2021 (Inception)
	Ended March 31, 2022			Through March 31, 2021
Redeemable Common Stock
Allocation of net loss	$	(122,049)	$	—
Denominator:
Weighted average shares of redeemable common stock outstanding		20,000,000		—
Basic and Diluted Net Loss per Redeemable Common Share	$	(0.01)	$	—
Non-Redeemable Common Stock
Allocation of net loss	$	(30,512)	$	(770)
Denominator:
Weighted average shares of non-redeemable common stock outstanding⁽¹⁾		5,000,000		5,000,000
Basic and Diluted Net Loss per Non-Redeemable Common Share	$	(0.01)	$	(0.00)

XML 28 R18.htm IDEA: XBRL DOCUMENT

Description of Organization and Business Operations (Details) - USD ($)		3 Months Ended
	Sep. 09, 2021	Mar. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance initial public offering		$ 201,000,000
Transaction Costs		21,881,745
Deferred underwriting and advisory fees payable		9,000,000	$ 9,000,000
Underwriting fees		4,019,555
Offering costs		21,881,745
Other offering costs		$ 8,163,891
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)		100.00%
Threshold period from closing of public offering entity is obligated to complete Business Combination		15 months
Threshold minimum aggregate fair market value as percentage of assets held in trust account		80.00%
Threshold percentage of outstanding voting securities of target to be acquired by post transaction company to complete business combination		50.00%
Common shares, par value, (per share)		$ 0.0001	$ 0.0001
Stock Price Per Unit		$ 10.05
Threshold Percentage of Public Shares Subject to Redemption Without Company's Prior Written Consent		15.00%
Threshold business days for redemption of public shares		10 days
Maximum Allowed Dissolution Expenses		$ 100,000
Operating bank accounts		1,129,587
Securities held in Trust Account		201,020,753
Working Capital		$ 1,282,177
Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants issued		7,375,000
Price of warrant	$ 1.00
Public Warrants
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants		$ 11.50
Number of warrants issued		10,000,000
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of units issued	20,000,000
Number of shares in a unit	1
Purchase price, per unit	$ 10.00
Redeemable per share		$ 10.05
Other offering costs		$ 698,299
Proceeds from IPO and Private Placement Warrants	$ 200,000,000
Common shares, par value, (per share)		$ 0.0001
Initial Public Offering \| Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit	0.5
Number of shares issuable per warrant	1
Exercise price of warrants	$ 11.50
Private Placement
Subsidiary, Sale of Stock [Line Items]
Number of warrants issued	7,375,000
Proceeds from sale of Private Placement Warrants	$ 7,375,000
Private Placement \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Number of shares issuable per warrant	1
Exercise price of warrants	$ 11.50
Number of warrants issued	7,375,000
Proceeds from sale of Private Placement Warrants	$ 7,375,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)		1 Months Ended	3 Months Ended
	Feb. 28, 2021	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies
Cash			$ 1,129,587	$ 1,446,482
Cash equivalents			0	0
Cash FDIC Insured Amount			250,000
Marketable securities held in trust			201,020,753	201,004,349
Offering costs			$ 21,881,745
Pre-Tax Book Loss (in percent)	21.00%	21.00%	21.00%
Unrecognized tax benefits accrued for interest and penalties			$ 0	0
Unrecognized tax benefits			$ 0	$ 0

XML 30 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Basic and diluted net loss per common share (Details) - USD ($)

1 Months Ended

3 Months Ended

Mar. 31, 2021

Mar. 31, 2022

Common stock subject to possible redemption

Numerator

Allocation of net income (loss)

$ (122,049)

Denominator

Weighted average shares outstanding, basic

20,000,000

Weighted average shares outstanding, diluted

20,000,000

Income/(Loss) earning per share, basic

$ (0.01)

Income/(Loss) earning per share, diluted

$ (0.01)

Common stock not subject to possible redemption

Numerator

Allocation of net income (loss)

$ (770)

$ (30,512)

Denominator

Weighted average shares outstanding, basic

^[1]

5,000,000

Weighted average shares outstanding, diluted

^[1]

5,000,000

Income/(Loss) earning per share, basic

$ 0.00

$ (0.01)

Income/(Loss) earning per share, diluted

$ 0.00

$ (0.01)

Founder Shares

Denominator

Number of shares issued

1,427,500

Cash exchange

$ 8,333

Founder Shares | Over-allotment option

Denominator

Maximum shares subject to forfeiture

750,000

[1]

XML 31 R21.htm IDEA: XBRL DOCUMENT

Public Offering (Details) - USD ($)	Sep. 09, 2021	Mar. 31, 2022
Public Warrants
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants		$ 11.50
Initial Public Offering
Subsidiary, Sale of Stock [Line Items]
Number of units issued	20,000,000
Purchase price, per unit	$ 10.00
Number of shares in a unit	1
Initial Public Offering \| Founder Shares
Subsidiary, Sale of Stock [Line Items]
Number of shares issued to each anchor investor	1,229,798
Purchase price of share by anchor investor	$ 0.0058
Excess fair value of shares	$ 8,163,891
Initial Public Offering \| Twelve Anchor Investors
Subsidiary, Sale of Stock [Line Items]
Number of units issued	19,480,000
Initial Public Offering \| Public Warrants
Subsidiary, Sale of Stock [Line Items]
Number of warrants in a unit	0.5
Number of shares issuable per warrant	1
Exercise price of warrants	$ 11.50
Private Placement
Subsidiary, Sale of Stock [Line Items]
Additional share purchase to an overallotment options	3,000,000
Overallotment options period	45 days

XML 32 R22.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Founder Shares (Details) - USD ($)

1 Months Ended

3 Months Ended

Jul. 16, 2021

Mar. 23, 2021

Mar. 03, 2021

Mar. 31, 2021

Mar. 31, 2022

Oct. 24, 2021

Aggregate purchase price

^[1]

$ 33,333

Cash from issuance of shares

$ 33,333

Founder Shares

Number of shares issued

1,437,500

4,312,500

Shares subject to forfeiture

562,500

Aggregate purchase price

$ 25,000

Initial investment by the founders

$ 25,000

Cash from issuance of shares

$ 8,333

Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination

1 year

Founder Shares | Minimum

Initial business combination trading day period

20 days

Founder Shares | Maximum

Initial business combination trading day period

30 days

Founder Shares | Class A Common Stock

Sale price of the Class A common stock equals or exceeds

$ 12.00

Founder Shares | Sponsor

Shares subject to forfeiture

187,500

Founder Shares | Sponsor | Over-allotment option

Shares subject to forfeiture

750,000

Founder Shares | Affiliates and Directors

Aggregate purchase price

$ 46,288

Aggregate sale of shares to founder

38,814

Purchase price, per unit

$ 0.0058

[1]

XML 33 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Related Party Loans (Details)	1 Months Ended	3 Months Ended
	Mar. 31, 2021 USD ($)	Mar. 31, 2022 USD ($) instrument
Related Party Transaction [Line Items]
Amount borrowed	$ 132,920
Related Party Loans
Related Party Transaction [Line Items]
Maximum borrowing capacity of related party promissory note		$ 250,000
Number of promissory notes \| instrument		2
Amount borrowed		$ 250,000
Outstanding balance of related party note		$ 0

XML 34 R24.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional information (Details) - USD ($)		3 Months Ended
	Sep. 09, 2021	Mar. 31, 2022
Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)		7,375,000
Threshold period for not to transfer, assign or sell any Warrants		30 days
Working capital loans
Subsidiary, Sale of Stock [Line Items]
Share Price		$ 1.00
Loan conversion agreement warrant		$ 2,000,000
Working capital loan, outstanding		$ 0
Private Placement
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	7,375,000
Proceeds from sale of Private Placement Warrants	$ 7,375,000
Private Placement \| Private Placement Warrants
Subsidiary, Sale of Stock [Line Items]
Sale of Private Placement Warrants (in shares)	7,375,000
Share Price	$ 1.00
Proceeds from sale of Private Placement Warrants	$ 7,375,000
Number of shares issuable per warrant	1
Exercise price of warrants	$ 11.50
Underwriting discounts and commissions	$ 0

XML 35 R25.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details)	3 Months Ended
Commitments and Contingencies (Details)	Mar. 31, 2022 USD ($)
Commitments and Contingencies.
Underwriting cash discount per unit	2.00%
Percentage of underwriting fees on gross offering proceeds	4.50%
Underwriting fees payable	$ 8,700,000
Financial advisory fee payable	$ 300,000
Variable portion of percentage of cash retained from the trust account paid to advisors	2.00%

XML 36 R26.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Preferred Stock (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Deficit
Preferred shares, shares authorized	5,000,000	5,000,000
Preferred stock, par value, (per share)	$ 0.0001	$ 0.0001
Preferred shares, shares issued	0	0
Preferred shares, shares outstanding	0	0

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Common Stock (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common shares, shares authorized (in shares)	500,000,000	500,000,000
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock including shares subject to possible redemption, issued (in shares)	25,000,000
Common stock including shares subject to possible redemption, outstanding (in shares)	25,000,000
Class A common stock subject to possible redemption, outstanding (in shares)	20,000,000	20,000,000
Common shares, redemption value per share \| $ / shares	$ 10.05	$ 10.05
Common shares, shares outstanding	5,000,000	5,000,000
Common stock subject to possible redemption
Class of Stock [Line Items]
Class A common stock subject to possible redemption, outstanding (in shares)	20,000,000
Common shares, redemption value per share \| $ / shares	$ 10.05

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit - Warrants (Details)	3 Months Ended
Stockholders' Deficit - Warrants (Details)	Mar. 31, 2022 D $ / shares
Class of Warrant or Right [Line Items]
Redemption period	30 days
Public Warrants
Class of Warrant or Right [Line Items]
Warrant exercise period condition	30 days
Period of time within which registration statement is expected to become effective	61 days
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.50
Public Warrants expiration term	5 years
Share Price	$ 9.20
Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant	60
Threshold number of specified trading period determining volume weighted average trading price	20 days
Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price	115.00%
Share price trigger used to measure dilution of warrant	$ 18.00
Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)	180.00%
Redemption price per public warrant (in dollars per share)	$ 0.01
Redemption period	30 days
Threshold trading days for redemption of public warrants	20 days
Threshold consecutive trading days for redemption of public warrants \| D	30
Private Placement Warrants
Class of Warrant or Right [Line Items]
Threshold period for not to transfer, assign or sell any Warrants	30 days

XML 39 fhltu-20220331x10q_htm.xml IDEA: XBRL DOCUMENT 0001851182 fhltu:CommonStockSubjectToRedemptionMember 2022-03-31 0001851182 us-gaap:AdditionalPaidInCapitalMember 2021-02-25 2021-03-31 0001851182 fhltu:FounderSharesMember 2021-03-03 2021-03-03 0001851182 us-gaap:CommonStockMember 2021-02-25 2021-03-31 0001851182 us-gaap:RetainedEarningsMember 2022-03-31 0001851182 us-gaap:RetainedEarningsMember 2021-12-31 0001851182 us-gaap:RetainedEarningsMember 2021-03-31 0001851182 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001851182 us-gaap:RetainedEarningsMember 2021-02-24 0001851182 us-gaap:AdditionalPaidInCapitalMember 2021-02-24 0001851182 2021-02-24 0001851182 us-gaap:IPOMember 2021-09-09 0001851182 fhltu:FounderSharesMember fhltu:AffiliatesAndDirectorsMember 2021-03-23 0001851182 fhltu:CommonStockSubjectToRedemptionMember us-gaap:CommonStockMember 2022-03-31 0001851182 us-gaap:CommonStockMember 2022-03-31 0001851182 fhltu:CommonStockSubjectToRedemptionMember us-gaap:CommonStockMember 2021-12-31 0001851182 us-gaap:CommonStockMember 2021-12-31 0001851182 us-gaap:CommonStockMember 2021-03-31 0001851182 fhltu:CommonStockSubjectToRedemptionMember us-gaap:CommonStockMember 2021-02-24 0001851182 us-gaap:CommonStockMember 2021-02-24 0001851182 fhltu:FounderSharesMember us-gaap:CommonClassAMember 2022-03-31 0001851182 fhltu:FounderSharesMember us-gaap:IPOMember 2021-09-09 0001851182 fhltu:RelatedPartyLoansMember 2022-01-01 2022-03-31 0001851182 fhltu:FounderSharesMember 2021-07-16 2021-07-16 0001851182 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001851182 us-gaap:RetainedEarningsMember 2021-02-25 2021-03-31 0001851182 2021-03-01 2021-03-31 0001851182 2021-02-25 2021-02-28 0001851182 fhltu:CommonStockSubjectToRedemptionMember 2022-01-01 2022-03-31 0001851182 fhltu:CommonStockNotSubjectToPossibleRedemptionMember 2022-01-01 2022-03-31 0001851182 fhltu:CommonStockNotSubjectToPossibleRedemptionMember 2021-02-25 2021-03-31 0001851182 fhltu:PrivatePlacementWarrantsMember 2022-03-31 0001851182 us-gaap:PrivatePlacementMember 2021-09-09 0001851182 fhltu:PublicWarrantsMember us-gaap:IPOMember 2021-09-09 0001851182 fhltu:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-09-09 0001851182 2021-02-25 2021-03-31 0001851182 2021-03-31 0001851182 fhltu:TwelveAnchorInvestorsMember us-gaap:IPOMember 2021-09-09 2021-09-09 0001851182 fhltu:PrivatePlacementWarrantsMember 2022-01-01 2022-03-31 0001851182 fhltu:FounderSharesMember 2022-01-01 2022-03-31 0001851182 fhltu:PublicWarrantsMember 2022-03-31 0001851182 fhltu:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-09-09 2021-09-09 0001851182 us-gaap:IPOMember 2022-03-31 0001851182 fhltu:FounderSharesMember fhltu:AffiliatesAndDirectorsMember 2021-03-23 2021-03-23 0001851182 us-gaap:IPOMember 2022-01-01 2022-03-31 0001851182 fhltu:PublicWarrantsMember us-gaap:IPOMember 2021-09-09 2021-09-09 0001851182 fhltu:FounderSharesMember fhltu:SponsorMember us-gaap:OverAllotmentOptionMember 2021-10-24 0001851182 fhltu:FounderSharesMember fhltu:SponsorMember 2021-07-16 0001851182 us-gaap:IPOMember 2021-09-09 2021-09-09 0001851182 fhltu:WorkingCapitalLoansWarrantMember 2022-03-31 0001851182 fhltu:FounderSharesMember us-gaap:OverAllotmentOptionMember 2021-03-31 0001851182 fhltu:RelatedPartyLoansMember 2022-03-31 0001851182 fhltu:FounderSharesMember 2021-03-03 0001851182 srt:MinimumMember fhltu:FounderSharesMember 2022-01-01 2022-03-31 0001851182 srt:MaximumMember fhltu:FounderSharesMember 2022-01-01 2022-03-31 0001851182 fhltu:FounderSharesMember us-gaap:IPOMember 2021-09-09 2021-09-09 0001851182 2021-12-31 0001851182 2022-03-31 0001851182 fhltu:PrivatePlacementWarrantsMember 2021-09-09 0001851182 fhltu:PublicWarrantsMember 2022-01-01 2022-03-31 0001851182 fhltu:FounderSharesMember 2021-02-25 2021-03-31 0001851182 us-gaap:PrivatePlacementMember 2021-09-09 2021-09-09 0001851182 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001851182 fhltu:UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember 2022-01-01 2022-03-31 0001851182 fhltu:RedeemableWarrantsExercisableForClassCommonStockMember 2022-01-01 2022-03-31 0001851182 2022-04-14 0001851182 2022-01-01 2022-03-31 shares iso4217:USD pure iso4217:USD shares fhltu:D fhltu:instrument Non-accelerated Filer

20000000

-0.01

5000000

-0.01

0.00

0001851182 --12-31 2022 Q1 false Yes Yes

20000000

-0.01

5000000

-0.01

0.00

25000000 0.5

20000000

5000000

0.5 P10D

5000000

10-Q true 2022-03-31 false 001-40788 Future Health ESG Corp. DE 86-2305680 8 The Green Suite 12081 Dover DE 19901 833 388-8734 Units, each consisting of one share of common stock and one-half of one redeemable warrant FHLTU NASDAQ Common stock par value $0.0001 per share FHLT NASDAQ Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share FHLTW NASDAQ true true false true 25000000

1129587

1446482

168916

108150

1298503

1554632

201020753

201004349

54076

74371

202373332

202633352

20904

62299

16326

40581

16326

123784

9000000 9000000

9016326

9123784

20000000

10.05

201000000

0.0001

5000000

0.0001

500000000

5000000

500

-7643494

-7490932

-7642994

-7490432

202373332

202633352

120284

778

50000

-170284

-778

1318

16404

-152562

-770

20000000

-0.01

5000000

-0.01

0.00

1427500

8333 750000

5750000

575

32758

33333

-770

5750000

575

32758

-770

32563

20000000

201000000

5000000

500

-7490932

-7490432

-152562

20000000

201000000

5000000

500

-7643494

-7642994

1427500

8333 750000

-152562

-770

16404

40471

179724

-107458

39249

-316895

-141245

132920

33333

166253

-316895

25008

1446482

1129587

25008

Note 1 — Description of Organization and Business OperationsOrganization and GeneralFuture Health ESG Corp. (the “Company”) is a blank check company incorporated in Delaware on February 25, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses (the “Business Combination”). The Company is an “emerging growth company”, and as such, the Company is subject to all the risks associated with emerging growth companies.As of March 31, 2022, the Company had not commenced any operations. All activity for the period from February 25, 2021 (inception) through March 31, 2022 relates to the Company’s formation, the initial public offering described below and, since the initial public offering, the search for a target business for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents held in the trust and operating accounts. The Company has selected December 31 as its fiscal year end.On September 9, 2021, (the “Company”) consummated its initial public offering (the “IPO”) of 20,000,000 units (the “Units”). Each Unit consists of one share of common stock and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one share of common stock for $11.50 per share, subject to adjustment. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $200,000,000, as further described in Note 3.Simultaneously with the closing of the Initial Public Offering, the Company completed the private sale of 7,375,000 warrants (the “Private Placement Warrants”) at a purchase price of $1.00 per Private Placement Warrant (the “Private Placement”) to Future Health ESG Associates 1, LLC (the “Sponsor”) and Cantor Fitzgerald & Co, generating gross proceeds to the Company of up to $7,375,000, as further described in Note 4.Transaction costs amounted to $21,881,745, including $9,000,000 in deferred underwriting and advisory fees payable, $4,019,555 in upfront underwriting fees, $8,163,891 in offering costs allocated to the fair value of the common shares offered to anchor investors by certain related parties (see Note 3), and $698,299 in other offering costs related to the Initial Public Offering.A total of $201,000,000 ($10.05 per redeemable share sold in the IPO), comprised of proceeds from the IPO and the sale of the Private Placement Warrants, was placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds held in the trust account that may be released to the Company to pay its taxes, if any, the funds held in the trust account will not be released from the trust account until the earliest of: (1) the completion of the Company’s initial business combination; (2) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemptions in connection with its initial business combination or to redeem 100% of its public shares if the Company does not complete its initial business combination within 15 months from the closing of the IPO (by December 14, 2022) or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of all of the Company’s public shares if it has not completed its initial business combination within 15 months from the closing of the IPO, subject to applicable law.The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in Trust and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company only intends to complete a Business Combination if the post-transaction company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”).The Company provides the holders (the “Public Stockholders”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share, sold in the Initial Public Offering (the “Public Shares”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders are entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (anticipated to be approximately $10.05 per Public Share). The per-share amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting and advisory fees the Company will pay to the underwriters (as discussed in Note 5). These Public Shares were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.”If the Company seeks stockholder approval, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by law, or the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem the Public Shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) have agreed to vote their Founder Shares (as defined below in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the initial stockholders have agreed to waive their redemption rights with respect to their Founder Shares and Public Shares in connection with the completion of a Business Combination.The Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the prior consent of the Company. The holders of the Founder Shares (the “initial stockholders”) have agreed not to propose an amendment to the Certificate of Incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (B) with respect to any other provision relating to stockholder’s rights or pre-initial Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.If the Company is unable to complete a Business Combination within 15 months from the closing of the Initial Public Offering (by December 14, 2022) (the “Combination Period”) and the Company’s stockholders have not amended the Certificate of Incorporation to extend such Combination Period, the Company will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably possible but no more than ten business days thereafter subject to lawfully available funds therefor, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses) divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.The initial stockholders have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting and advisory fees (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.05. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement (a “Target”), reduce the amount of funds in the Trust Account to below (i) $10.05 per Public Share or (ii) the lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, in each case net of interest which may be withdrawn to pay taxes, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to seek access to the Trust Account nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, our sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.COVID-19On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus (the “COVID-19 outbreak”). In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve. Management continues to evaluate the impact of the COVID-19 outbreak on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited financial statements. The unaudited financial statements do not include any adjustments to reflect the outcome of this uncertainty.Going ConcernOn a routine basis, the Company assesses going concern considerations in accordance with ASC 205-40, “Presentation of Financial Statements - Going Concern”. As of March 31, 2022, we had $1,129,587 in our operating bank account, $1,282,177 of working capital, and $201,020,753 of securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem our common stock in connection therewith. We believe that we will have sufficient working capital and borrowing capacity to meet our needs through the earlier of the consummation of a Business Combination or one year from this filing, however, there is a risk that our liquidity may not be sufficient. The Sponsor intends, but is not obligated to, provide us with Working Capital Loans to sustain operations in the event of a liquidity deficiency.We have until December 14, 2022 to consummate a Business Combination. If a Business Combination is not consummated by this date and an extension is not requested by the Sponsor there will be a mandatory liquidation and subsequent dissolution of the Company. While Management expects to complete a Business Combination prior to December 14, 2022, this date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The unaudited financial statements do not include any adjustments that might result from the outcome of this uncertainty.

20000000 1

11.50

10.00

200000000

7375000

1.00

7375000

21881745 9000000 4019555 8163891 698299

201000000

10.05 1 P15M P15M 0.80 0.50

0.0001

10.05 0.15 1 P15M 100000 10.05 10.05 1129587 1282177 201020753

Note 2 — Summary of Significant Accounting Policies Basis of PresentationThe accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.Emerging Growth CompanyThe Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.Use of EstimatesThe preparation of unaudited financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements and the reported amounts of income and expenses during the reporting period.Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.Net Loss Per Share of Common StockEarnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares issued and outstanding during the period. Earnings and losses are allocated to redeemable and non-redeemable common stock based on weighted-average shares outstanding. The Company has not considered the effect of warrants sold in the Initial Public Offering and private placement to purchase common stock in the calculation of diluted (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events.The Company’s statement of operations includes a presentation of loss per share of common stock subject to possible redemption in a manner similar to the two-class method of loss per share. As of March 31, 2022 and 2021, the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. Remeasurement adjustment on redeemable common stock is not considered in the calculation because redemption value closely approximates fair value.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;">For the Period From</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;margin:0pt;padding:0pt;">For the Three Months</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;">February 25, 2021 (Inception)</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Ended March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Through March 31, 2021</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Redeemable Common Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Allocation of net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> (122,049)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Denominator:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Weighted average shares of redeemable common stock outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,000,000</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Basic and Diluted Net Loss per Redeemable Common Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Non-Redeemable Common Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Allocation of net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> (30,512)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> (770)</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Denominator:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Weighted average shares of non-redeemable common stock outstanding(1)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Basic and Diluted Net Loss per Non-Redeemable Common Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> (0.01)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> (0.00)</td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;">(1)For the period from February 25, 2021 (Inception) through March 31, 2021, includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and excludes an aggregate of 750,000 founder shares forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4).</div>Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of the date of this quarterly report, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.Fair Value of Financial InstrumentsThe Company applies ASC 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:Level 1 – Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 – Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The Company’s marketable securities held in trust of $201,020,753 as of March 31, 2022, and $201,004,349 as of December 31, 2021 are deemed cash and cash equivalents which are considered level 1 classified. There were no transfers to and from Levels 1, 2, and 3 during the three months ended March 31, 2022, or the period from February 25, 2021 (inception) through March 31, 2021.Offering CostsOffering costs consist of legal, accounting, and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering and were allocated to temporary equity or stockholders' deficit upon the completion of the Initial Public Offering. Offering costs were $21,881,745. The Company complies with the requirements of the ASC 340-10-S99-1.WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The Company must then present them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the Company’s warrants defined in Note 6 do not exhibit any of the above characteristics and, therefore are outside the scope of ASC 480.For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The 10,000,000 Public Warrants and 7,375,000 Private Placement Warrants, excluding over-allotment, were issued in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants meet the criteria for equity treatment thereunder, each warrant will be recorded as equity. The Company, therefore, accounts for its outstanding warrants as equity-classified instruments.Income TaxesThe Company complies with the accounting and reporting requirements of ASC, 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.There were no unrecognized tax benefits as of March 31, 2022 or December 31, 2021. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The effective tax rate differs from the statutory rate of 21% for the three months ended March 31, 2022 and the period from February 25, 2021 (Inception) through March 31, 2021 due to the valuation allowance recorded against the deferred tax benefit relating to the Company’s net operating losses.Recent Accounting PronouncementsIn August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020- 06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years beginning after December 15, 2021 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company early adopted ASU 2020-06 effective upon inception on February 25, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s unaudited financial statements.The Company’s management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the accompanying unaudited financial statements.Cash and Cash EquivalentsThe Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $1,129,587 and $1,446,482 in cash (and no cash equivalents) as of March 31, 2022 and December 31, 2021, respectively.Marketable Securities Held in Trust AccountAs of the date of this quarterly report, the assets held in the Trust Account were held in investments in money market funds.Common Stock Subject to Possible RedemptionThe Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including shares of common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ deficit. The Company’s common stock represented by Public Shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, all common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, the Company recognized the remeasurement of initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital, to the extent available, and accumulated deficit.

Basis of PresentationThe accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 28, 2022, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2021 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The interim results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any future interim periods.

Emerging Growth CompanyThe Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of EstimatesThe preparation of unaudited financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements and the reported amounts of income and expenses during the reporting period.Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Net Loss Per Share of Common StockEarnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares issued and outstanding during the period. Earnings and losses are allocated to redeemable and non-redeemable common stock based on weighted-average shares outstanding. The Company has not considered the effect of warrants sold in the Initial Public Offering and private placement to purchase common stock in the calculation of diluted (loss) per share, since the exercise of the warrants are contingent upon the occurrence of future events.The Company’s statement of operations includes a presentation of loss per share of common stock subject to possible redemption in a manner similar to the two-class method of loss per share. As of March 31, 2022 and 2021, the Company did not have any other dilutive securities and other contracts that could, potentially, be exercised or converted into common shares and then share in the earnings of the Company. As a result, diluted loss per share is the same as basic loss per share for the periods presented. Remeasurement adjustment on redeemable common stock is not considered in the calculation because redemption value closely approximates fair value.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;">For the Period From</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;margin:0pt;padding:0pt;">For the Three Months</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;">February 25, 2021 (Inception)</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Ended March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Through March 31, 2021</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Redeemable Common Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Allocation of net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> (122,049)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Denominator:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Weighted average shares of redeemable common stock outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,000,000</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Basic and Diluted Net Loss per Redeemable Common Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Non-Redeemable Common Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Allocation of net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> (30,512)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> (770)</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Denominator:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Weighted average shares of non-redeemable common stock outstanding(1)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Basic and Diluted Net Loss per Non-Redeemable Common Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> (0.01)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> (0.00)</td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;">(1)For the period from February 25, 2021 (Inception) through March 31, 2021, includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and excludes an aggregate of 750,000 founder shares forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4).</div>

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;">For the Period From</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;margin:0pt;padding:0pt;">For the Three Months</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;">February 25, 2021 (Inception)</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Ended March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Through March 31, 2021</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Redeemable Common Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Allocation of net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> (122,049)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Denominator:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Weighted average shares of redeemable common stock outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,000,000</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Basic and Diluted Net Loss per Redeemable Common Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> (0.01)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Non-Redeemable Common Stock</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Allocation of net loss</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"> (30,512)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;margin:0pt;padding:0pt;"> (770)</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Denominator:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.93%;background:#cceeff;margin:0pt;padding:0pt;">Weighted average shares of non-redeemable common stock outstanding(1)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,000,000</td></tr><tr><td style="vertical-align:bottom;width:59.93%;margin:0pt;padding:0pt;">Basic and Diluted Net Loss per Non-Redeemable Common Share</td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"> (0.01)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:18.93%;margin:0pt;padding:0pt;"> (0.00)</td></tr></table>

-122049

20000000

-0.01

-30512

-770

5000000

-0.01

0.00

1427500

8333 750000

Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. As of the date of this quarterly report, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

250000

Fair Value of Financial InstrumentsThe Company applies ASC 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances. The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:Level 1 – Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 – Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The Company’s marketable securities held in trust of $201,020,753 as of March 31, 2022, and $201,004,349 as of December 31, 2021 are deemed cash and cash equivalents which are considered level 1 classified. There were no transfers to and from Levels 1, 2, and 3 during the three months ended March 31, 2022, or the period from February 25, 2021 (inception) through March 31, 2021.

201020753

201004349

Offering CostsOffering costs consist of legal, accounting, and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering and were allocated to temporary equity or stockholders' deficit upon the completion of the Initial Public Offering. Offering costs were $21,881,745. The Company complies with the requirements of the ASC 340-10-S99-1.

21881745 WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.ASC 480-10-S99 addresses concerns raised by the SEC regarding the financial statement classification and measurement of securities subject to mandatory redemption requirements or whose redemption is outside the control of the issuer. If the stock subject to mandatory redemption provisions represents the only shares in the reporting entity, it must report instruments in the liabilities section of its statement of financial position. The Company must then present them as shares subject to mandatory redemption, so as to distinguish the instruments from other financial statement liabilities. The Company concludes that the Company’s warrants defined in Note 6 do not exhibit any of the above characteristics and, therefore are outside the scope of ASC 480.For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The 10,000,000 Public Warrants and 7,375,000 Private Placement Warrants, excluding over-allotment, were issued in accordance with the guidance contained in ASC 815-40. Such guidance provides that because the warrants meet the criteria for equity treatment thereunder, each warrant will be recorded as equity. The Company, therefore, accounts for its outstanding warrants as equity-classified instruments.

10000000

7375000

Income TaxesThe Company complies with the accounting and reporting requirements of ASC, 740, “Income Taxes,” which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.There were no unrecognized tax benefits as of March 31, 2022 or December 31, 2021. ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties at March 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The effective tax rate differs from the statutory rate of 21% for the three months ended March 31, 2022 and the period from February 25, 2021 (Inception) through March 31, 2021 due to the valuation allowance recorded against the deferred tax benefit relating to the Company’s net operating losses.

0.21

Recent Accounting PronouncementsIn August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020- 06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years beginning after December 15, 2021 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company early adopted ASU 2020-06 effective upon inception on February 25, 2021. The adoption of ASU 2020-06 did not have an impact on the Company’s unaudited financial statements.The Company’s management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the accompanying unaudited financial statements.

Cash and Cash EquivalentsThe Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $1,129,587 and $1,446,482 in cash (and no cash equivalents) as of March 31, 2022 and December 31, 2021, respectively.

1129587

1446482

Marketable Securities Held in Trust AccountAs of the date of this quarterly report, the assets held in the Trust Account were held in investments in money market funds. Common Stock Subject to Possible RedemptionThe Company accounts for its common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of common stock subject to mandatory redemption is classified as a liability instrument and measured at fair value. Conditionally redeemable common stock (including shares of common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ deficit. The Company’s common stock represented by Public Shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, all common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ deficit section of the Company’s balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Immediately upon the closing of the IPO, the Company recognized the remeasurement of initial book value to redemption amount value. The change in the carrying value of redeemable common stock resulted in charges against additional paid-in capital, to the extent available, and accumulated deficit. Note 3 — Public Offering Pursuant to the Initial Public Offering, the Company sold 20,000,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one share of common stock and one-half of one Public Warrant. Each whole Public Warrant entitles the holder to purchase one share of common stock at an exercise price of $11.50 per share.Twelve anchor investors, none of whom is affiliated with any member of our management team, purchased an aggregate of 19,480,000 of the units sold in the Initial Public Offering. Further, each such anchor investor purchased a pro-rata portion of 1,229,798 Founder Shares (defined below) from MB Equity, LLC, an affiliate of Bradley Bostic, the Company’s Chief Executive Officer and a director, and Travis Morgan, the Company’s Chief Financial Officer, and a director, at a price of $0.0058 per share.The Company has determined the excess fair value of the Founder Shares sold to the anchor investors to be $8,163,891. To estimate the fair value, management considered the probability and timing of IPO completion, business combination completion, and an appropriate discount for lack of marketability, all Level 3 Inputs under ASC 820. The excess of the fair value of the Founder Shares was determined to be an offering cost in accordance with Staff Accounting Bulletin Topic 5A and was charged to common stock subject to possible redemption upon completion of the Initial Public Offering. In accordance with Staff Accounting Bulletin Topic 5T, a capital contribution from the founders was recorded in additional paid-in capital.The underwriter did not exercise their overallotment option to purchase an additional 3,000,000 private warrants within the 45 day limit. Management determined the fair value of this option to be immaterial, therefore, the unaudited financial statements do not include any adjustments relating to the expiration of the overallotment option. 20000000

10.00

11.50

19480000 1229798

0.0058

8163891 3000000 P45D

Note 4 — Related Party TransactionsFounder SharesOn March 3, 2021, entities affiliated with our executive officers acquired 4,312,500 founder shares, up to 562,500 of which were subject to forfeiture (the “Founder Shares”), for an aggregate purchase price of $25,000. Prior to the initial investment in the Company of $25,000 by our founders, we had no assets, tangible, or intangible. On July 16, 2021, the Company issued an additional 1,437,500 Founder Shares to the Sponsor, up to 187,500 of which were subject to forfeiture, in exchange for $8,333 in cash. All shares and associated amounts have been retroactively restated in the period from February 25, 2021 (Inception) through March 31, 2021 to reflect the additional founder shares. A total of 750,000 founder shares were forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021.The Company’s initial stockholders, officers and directors have agreed not to transfer, assign or sell any Founder Shares held by them until the earlier to occur of: (1) one year after the completion of the initial Business Combination; and (2) subsequent to the initial Business Combination, (x) the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the public stockholders having the right to exchange their shares of common stock for cash, securities or other property or (y) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at the initial Business Combination. Any permitted transferees would be subject to the same restrictions and other agreements of the initial stockholders with respect to any Founder Shares (the “Lock-up”).On March 23, 2021, the Sponsor sold an aggregate of 38,814 founder shares to directors at a price of $0.0058 per share. The Company determined the excess fair value over consideration paid for the founder shares transferred to be $46,288 as of the grant date. To estimate the fair value, management considered the probability and timing of IPO completion, business combination completion, and an appropriate discount for lack of marketability, all Level 3 Inputs under ASC 820.The sale of Founder Shares to members of the Company’s board of directors is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity classified awards is measured at fair value upon the grant date. The Founder Shares were effectively sold or transferred subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. A business combination is not probable until it is completed. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founder Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares. As of March 31, 2022, a business combination had not yet been completed, therefore, no stock-based compensation expense has been recognized.Related Party LoansFuture Health ESG Associates 1, LLC agreed to loan the Company up to $250,000 to cover expenses related to the Initial Public Offering pursuant to two promissory notes dated March 4, 2021 and August 24, 2021. These notes are non-interest bearing and payable on the earlier of March 31, 2022 and the closing of the Initial Public Offering. The Company borrowed a total of $250,000 prior to the Initial Public Offering, and subsequently repaid the full balance after the closing of the Initial Public Offering. There was no outstanding balance on the notes as of the date of this quarterly report.Private Placement Warrants On September 9, 2021, the Company entered into Private Placement Warrants Purchase Agreements for the private sale (the “Private Placement”) of 7,375,000 warrants to its initial stockholders and Cantor Fitzgerald & Co (such warrants, collectively, the “Private Placement Warrants”), at a purchase price of $1.00 per Private Placement Warrant, for gross proceeds to the Company of up to $7,375,000. Each whole warrant entitles the holder thereof to purchase one share of Common Stock for $11.50 per share, subject to adjustment. No underwriting discounts or commissions were paid with respect to the Private Placement. The Private Placement was conducted as a non-public transaction pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933 (as amended, the “Securities Act”).The purchasers of the Private Placement Warrants have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Private Placement Warrants (except to permitted transferees) until 30 days after the completion of the initial Business Combination. Working Capital LoansIn order to finance transaction costs in connection with a Business Combination, the Sponsor, or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender’s discretion, up to $2,000,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. To date, the Company had no borrowings under the Working Capital Loans.

4312500

562500

25000

1437500

187500

8333

750000 P1Y

12.00

P20D P30D 38814

0.0058

46288

250000 2

250000

7375000

1.00

7375000

11.50

0 P30D 2000000

1.00

Note 5 — Commitments and ContingenciesRegistration RightsThe holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any (and any shares of common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans), are entitled to registration rights pursuant to a registration rights agreement. These holders are entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that we will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.Underwriting Agreement and Advisory FeesThe Company paid an underwriting discount of 2.0% of the per Unit offering price to Cantor Fitzgerald & Co at the closing of the Initial Public Offering, with an additional fee of 4.5% of the gross offering proceeds payable only upon the Company’s completion of its Initial Business Combination, of which $8,700,000 will be paid to Cantor Fitzgerald & Co and $300,000 will be paid to Roth Capital Partners, LLC, an independent financial advisor to the Company.The Company has entered into capital markets advisory agreements with multiple advisors pursuant to which fees will be paid in an aggregate amount of up to 2% of the cash retained from the trust account (net of redemptions) plus any gross proceeds raised in a financing relating to an Initial Business Combination. The capital markets advisory fees are contingent on both the consummation and the specific terms of an Initial Business Combination, neither of which can be reasonably predicted at this time. Accordingly, no accrual has been made for these arrangements in the unaudited financial statements.

0.020 0.045 8700000 300000 0.02

Note 6 — Stockholders’ DeficitPreferred Stock — The Company is authorized to issue 5,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s Board of Directors. As of the date of this quarterly report, there were no shares of preferred stock issued or outstanding.Common Stock — The Company is authorized to issue 500,000,000 shares of common stock with a par value of $0.0001 per share. As of December 31, 2021, there were 25,000,000 shares of common stock issued and outstanding. Up to 20,000,000 of outstanding common stock shares were issued in conjunction with the IPO and are redeemable at a price of $10.05 per share. Redeemable common stock shares are classified as temporary equity and are excluded from total stockholders' deficit. The remaining 5,000,000 outstanding shares of common stock are non-redeemable Founder Shares and are included in total stockholders’ deficit.Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants were issued upon separation of the Units (which occurred on December 9, 2021) and only whole Public Warrants will trade. The Public Warrants will become exercisable 30 days after the completion of a Business Combination. The Company has agreed that as soon as practicable after the closing of its initial Business Combination, the Company will use its best efforts to file with the SEC and have an effective registration statement covering the shares of common stock issuable upon exercise of the warrants and will use its best efforts to cause the same to become effective and to maintain a current prospectus relating to those shares of common stock until the warrants expire or are redeemed. If, at any time beginning on the 61st business day after the closing of our initial business combination, the shares of common stock issuable upon exercise of the public warrants are not covered by an effective registration statement, the holders of the public warrants will be entitled to exercise such warrants on a cashless basis. However, no public warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.Both Public and Private Warrants have an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. In addition, if, in connection with an initial business combination, (x) the Company issues additional shares of common stock or equity-linked securities at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price as determined in good faith by the board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Business Combination on the date of the consummation of such Business Combination (net of redemptions) and (z) the volume weighted average trading price of common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below will be adjusted (to the nearest cent) to be equal to 180% of the greater of the Market Value and the Newly Issued Price.The Private Placement Warrants are identical to the Public Warrants, except that (i) they will not be redeemable by the Company, (ii) they may not, subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of the initial Business Combination, (iii) they may be exercised by the holders on a cashless basis, (iv) they are subject to registration rights and (v) Cantor Fitzgerald & Co. has agreed that it shall have the right to exercise the Private Placement Warrants until, and shall forfeit to us for cancellation any Private Placement Warrants held by it on, the date that is five years after the effective date of the registration statement of which this prospectus forms a part in accordance with FINRA Rule 5110(g)(8)(A).Redemption of public warrants: Once the public warrants become exercisable, the Company may redeem the outstanding public warrants for cash (except as described herein with respect to the Private Placement Warrants):<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">In whole and not in part;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">At a price of $0.01 per warrant;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Upon a minimum of 30 days’ prior written notice of redemption; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">if, and only if, the last reported sale price of our common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders.</td></tr></table><div style="margin-top:8pt;"/>The Company will not redeem the warrants for cash as described above unless an effective registration statement under the Securities Act covering the shares of common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of common stock is available throughout the 30-day redemption period. Any such exercise would not be on a cashless basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised.In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

5000000

0.0001

500000000

0.0001

25000000

20000000

10.05

5000000

P30D P61D

11.50

P5Y

9.20

60 P20D

9.20

1.15 18.00 1.80 P30D 0.01 P30D 18.00 P20D 30 P30D

Note 7 — Subsequent EventsManagement has evaluated the impact of subsequent events that occurred after the balance sheet date up to the date the unaudited financial statements were issued and has not identified any subsequent events that would have required adjustment or disclosure in the unaudited financial statements.

Includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and also includes an aggregate of 750,000 founder shares issued and outstanding at March 31, 2021 that were forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4). For the period from February 25, 2021 (Inception) through March 31, 2021, includes a retrospective restatement of 1,427,500 founder shares issued on July 16, 2021, in exchange for $8,333 in cash, and excludes an aggregate of 750,000 founder shares forfeited by the Sponsor and affiliated entities upon the expiration of the Underwriter’s Overallotment option on October 24, 2021 (see Note 4).

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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
*CE123-2<$P, ((3 / " 4W+ !X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #'BHY4+P""5$P! !K$0 &@ M @ &-S@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " #'BHY4(N!HUWL! Z$@ $P @ $1T 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 ) D +,) "]T0 ! end XML 41 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 67 178 1 true 23 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - BALANCE SHEETS Sheet http://futurehealthesgcorp.com/role/StatementBalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - UNAUDITED STATEMENTS OF OPERATIONS Sheet http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations UNAUDITED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00205 - Statement - UNAUDITED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical UNAUDITED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 00300 - Statement - UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 00305 - Statement - UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S EQUITY (DEFICIT) (Parenthetical) Sheet http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S EQUITY (DEFICIT) (Parenthetical) Statements 7 false false R8.htm 00400 - Statement - UNAUDITED STATEMENTS OF CASH FLOWS Sheet http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows UNAUDITED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 10101 - Disclosure - Description of Organization and Business Operations Sheet http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations Description of Organization and Business Operations Notes 9 false false R10.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 10301 - Disclosure - Public Offering Sheet http://futurehealthesgcorp.com/role/DisclosurePublicOffering Public Offering Notes 11 false false R12.htm 10401 - Disclosure - Related Party Transactions Sheet http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 10501 - Disclosure - Commitments and Contingencies Sheet http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 10601 - Disclosure - Stockholders' Deficit Sheet http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficit Stockholders' Deficit Notes 14 false false R15.htm 10701 - Disclosure - Subsequent Events Sheet http://futurehealthesgcorp.com/role/DisclosureSubsequentEvents Subsequent Events Notes 15 false false R16.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies 16 false false R17.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 40101 - Disclosure - Description of Organization and Business Operations (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails Description of Organization and Business Operations (Details) Details http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations 18 false false R19.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 19 false false R20.htm 40202 - Disclosure - Summary of Significant Accounting Policies - Basic and diluted net loss per common share (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails Summary of Significant Accounting Policies - Basic and diluted net loss per common share (Details) Details 20 false false R21.htm 40301 - Disclosure - Public Offering (Details) Sheet http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails Public Offering (Details) Details http://futurehealthesgcorp.com/role/DisclosurePublicOffering 21 false false R22.htm 40401 - Disclosure - Related Party Transactions - Founder Shares (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails Related Party Transactions - Founder Shares (Details) Details 22 false false R23.htm 40402 - Disclosure - Related Party Transactions - Related Party Loans (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails Related Party Transactions - Related Party Loans (Details) Details 23 false false R24.htm 40403 - Disclosure - Related Party Transactions - Additional information (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional information (Details) Details 24 false false R25.htm 40501 - Disclosure - Commitments and Contingencies (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingencies 25 false false R26.htm 40601 - Disclosure - Stockholders' Deficit - Preferred Stock (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitPreferredStockDetails Stockholders' Deficit - Preferred Stock (Details) Details 26 false false R27.htm 40602 - Disclosure - Stockholders' Deficit - Common Stock (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails Stockholders' Deficit - Common Stock (Details) Details 27 false false R28.htm 40603 - Disclosure - Stockholders' Deficit - Warrants (Details) Sheet http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails Stockholders' Deficit - Warrants (Details) Details 28 false false All Reports Book All Reports fhltu-20220331x10q.htm fhltu-20220331.xsd fhltu-20220331_cal.xml fhltu-20220331_def.xml fhltu-20220331_lab.xml fhltu-20220331_pre.xml fhltu-20220331xex31d1.htm fhltu-20220331xex31d2.htm fhltu-20220331xex32d1.htm fhltu-20220331xex32d2.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 46 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "fhltu-20220331x10q.htm": { "axisCustom": 0, "axisStandard": 7, "contextCount": 67, "dts": { "calculationLink": { "local": [ "fhltu-20220331_cal.xml" ] }, "definitionLink": { "local": [ "fhltu-20220331_def.xml" ] }, "inline": { "local": [ "fhltu-20220331x10q.htm" ] }, "labelLink": { "local": [ "fhltu-20220331_lab.xml" ] }, "presentationLink": { "local": [ "fhltu-20220331_pre.xml" ] }, "schema": { "local": [ "fhltu-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 251, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 23, "http://futurehealthesgcorp.com/20220331": 4, "http://xbrl.sec.gov/dei/2021q4": 8, "total": 35 }, "keyCustom": 62, "keyStandard": 116, "memberCustom": 12, "memberStandard": 9, "nsprefix": "fhltu", "nsuri": "http://futurehealthesgcorp.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies", "role": "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "fhltu:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Public Offering", "role": "http://futurehealthesgcorp.com/role/DisclosurePublicOffering", "shortName": "Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "fhltu:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Related Party Transactions", "role": "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Commitments and Contingencies", "role": "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Stockholders' Deficit", "role": "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficit", "shortName": "Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Subsequent Events", "role": "http://futurehealthesgcorp.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Description of Organization and Business Operations (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "shortName": "Description of Organization and Business Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - BALANCE SHEETS", "role": "http://futurehealthesgcorp.com/role/StatementBalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_fhltu_CommonStockSubjectToRedemptionMember_ECXaLGv8S0-dvW24KGEYqg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Basic and diluted net loss per common share (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "shortName": "Summary of Significant Accounting Policies - Basic and diluted net loss per common share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_fhltu_CommonStockSubjectToRedemptionMember_ECXaLGv8S0-dvW24KGEYqg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_ClassOfWarrantOrRightAxis_fhltu_PublicWarrantsMember_sKRLkmxtxkq7HGNWqvB2Pg", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_Bk_Sz56tJUm8CE0xgD_SLw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Public Offering (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "shortName": "Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_9_9_2021_To_9_9_2021_us-gaap_RelatedPartyTransactionAxis_fhltu_FounderSharesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Phh0iKPzvU2UdN_xaim0UA", "decimals": "INF", "lang": null, "name": "fhltu:NumberOfSharesIssuedToEachAnchorInvestor", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_NfjRjYtZI0mWA04h-cQT6w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Related Party Transactions - Founder Shares (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "shortName": "Related Party Transactions - Founder Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_7_16_2021_To_7_16_2021_us-gaap_RelatedPartyTransactionAxis_fhltu_FounderSharesMember_nf4qAjVxD0SBYng88d4mpA", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_NfjRjYtZI0mWA04h-cQT6w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Related Party Transactions - Related Party Loans (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails", "shortName": "Related Party Transactions - Related Party Loans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_RelatedPartyTransactionAxis_fhltu_RelatedPartyLoansMember_l2B8R_3OC0OjYXOBA4Ypeg", "decimals": "0", "lang": null, "name": "fhltu:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "fhltu:WarrantsPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_ClassOfWarrantOrRightAxis_fhltu_PrivatePlacementWarrantsMember_GmUOj9nZV06K90mGajlc6g", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Related Party Transactions - Additional information (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_ClassOfWarrantOrRightAxis_fhltu_WorkingCapitalLoansWarrantMember_b_Qw_KrH-k6lcZnz1p3U7g", "decimals": "2", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_Bk_Sz56tJUm8CE0xgD_SLw", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": "3", "first": true, "lang": null, "name": "fhltu:UnderwritingCashDiscountPerUnit.", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_JBsoMBF8w0qhQdbIbhPZEA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Commitments and Contingencies (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": "3", "first": true, "lang": null, "name": "fhltu:UnderwritingCashDiscountPerUnit.", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_JBsoMBF8w0qhQdbIbhPZEA", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Stockholders' Deficit - Preferred Stock (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitPreferredStockDetails", "shortName": "Stockholders' Deficit - Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Stockholders' Deficit - Common Stock (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "shortName": "Stockholders' Deficit - Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "INF", "lang": null, "name": "fhltu:CommonStockSharesIncludingTemporaryEquityIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "fhltu:RedemptionPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Stockholders' Deficit - Warrants (Details)", "role": "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails", "shortName": "Stockholders' Deficit - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "fhltu:RedemptionPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_K_V2DLh4dk2m-G6d-Vz2Jg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - BALANCE SHEETS (Parenthetical)", "role": "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_NfjRjYtZI0mWA04h-cQT6w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - UNAUDITED STATEMENTS OF OPERATIONS", "role": "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations", "shortName": "UNAUDITED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_NfjRjYtZI0mWA04h-cQT6w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "link:footnote", "div", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_fhltu_FounderSharesMember_IJsY9sKMzUeI3nUjUS0Duw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00205 - Statement - UNAUDITED STATEMENTS OF OPERATIONS (Parenthetical)", "role": "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical", "shortName": "UNAUDITED STATEMENTS OF OPERATIONS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_2_24_2021_us-gaap_StatementClassOfStockAxis_fhltu_CommonStockSubjectToRedemptionMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ODXaixd00CdxrHkutPkjQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "shortName": "UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "As_Of_2_24_2021_us-gaap_StatementClassOfStockAxis_fhltu_CommonStockSubjectToRedemptionMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-ODXaixd00CdxrHkutPkjQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "link:footnote", "div", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_fhltu_FounderSharesMember_IJsY9sKMzUeI3nUjUS0Duw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Unit_Standard_shares_aHj45WNygkCGyLUH3KlV1w", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S EQUITY (DEFICIT) (Parenthetical)", "role": "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "shortName": "UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDER'S EQUITY (DEFICIT) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_NfjRjYtZI0mWA04h-cQT6w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - UNAUDITED STATEMENTS OF CASH FLOWS", "role": "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows", "shortName": "UNAUDITED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_2_25_2021_To_3_31_2021_NfjRjYtZI0mWA04h-cQT6w", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_NGXrAEuPBU-JFPHuqY2ALA", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Description of Organization and Business Operations", "role": "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations", "shortName": "Description of Organization and Business Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "fhltu-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_xYHbMju_zk-xTkfS2M3smQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 23, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "fhltu_AdditionalSharePurchaseToOverallotmentOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares to represents the number of Additional Share Purchase To An Overallotment Options.", "label": "Additional Share Purchase To An Overallotment Options", "terseLabel": "Additional share purchase to an overallotment options" } } }, "localname": "AdditionalSharePurchaseToOverallotmentOptions", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "fhltu_AffiliatesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Person serving on affiliates and board of directors.", "label": "Affiliates and Directors" } } }, "localname": "AffiliatesAndDirectorsMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "fhltu_AssetsHeldInTrustAccountPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for assets held in trust.", "label": "Assets Held In Trust Account, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fhltu_CashExchange": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash exchange.", "label": "Cash Exchange", "terseLabel": "Cash exchange" } } }, "localname": "CashExchange", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "fhltu_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price", "terseLabel": "Class Of Warrant Or Right Adjustment Of Exercise Price Of Warrants Or Rights Percent Based On Market Value And Newly Issued Price" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "percentItemType" }, "fhltu_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of redemption price of stock based on market value and newly issued price.", "label": "Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1", "terseLabel": "Adjustment one of redemption price of stock based on market value and newly issued price (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "percentItemType" }, "fhltu_ClassOfWarrantOrRightPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Price of Warrants or Rights", "terseLabel": "Price of warrant" } } }, "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "fhltu_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "integerItemType" }, "fhltu_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "fhltu_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights", "terseLabel": "Redemption price per public warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "perShareItemType" }, "fhltu_CommonStockIncludingTemporaryEquitySharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock including temporary equity outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Including Temporary Equity, Shares, Outstanding", "terseLabel": "Common stock including shares subject to possible redemption, outstanding (in shares)" } } }, "localname": "CommonStockIncludingTemporaryEquitySharesOutstanding", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails" ], "xbrltype": "sharesItemType" }, "fhltu_CommonStockNotSubjectToPossibleRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing common stock not subject \nto possible redemption.", "label": "Common stock not subject to possible redemption" } } }, "localname": "CommonStockNotSubjectToPossibleRedemptionMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "fhltu_CommonStockSharesIncludingTemporaryEquityIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of common shares including temporary equity of an entity that have been sold or granted to shareholders.", "label": "Common Stock, Shares, Including Temporary Equity, Issued", "terseLabel": "Common stock including shares subject to possible redemption, issued (in shares)" } } }, "localname": "CommonStockSharesIncludingTemporaryEquityIssued", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails" ], "xbrltype": "sharesItemType" }, "fhltu_CommonStockSubjectToRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing shares subject to possible redemption.", "label": "Common stock subject to possible redemption" } } }, "localname": "CommonStockSubjectToRedemptionMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "fhltu_DeferredOfferingCostsNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.", "label": "Underwriting fees payable" } } }, "localname": "DeferredOfferingCostsNoncurrent", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_DeferredUnderwritingAndAdvisoryFeesPayableNoncurrent": { "auth_ref": [], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting and advisory fee payable classified as noncurrent.", "label": "Deferred Underwriting and Advisory Fees Payable, Noncurrent", "terseLabel": "Deferred underwriting and advisory fees payable" } } }, "localname": "DeferredUnderwritingAndAdvisoryFeesPayableNoncurrent", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "fhltu_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Denominator" } } }, "localname": "DenominatorAbstract", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "fhltu_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on Emerging Growth Company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fhltu_ExcessFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount refers to excess fair value of shares", "label": "Excess Fair Value", "terseLabel": "Excess fair value of shares" } } }, "localname": "ExcessFairValue", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_FinancialAdvisoryFeePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount refers to financial advisory fee payable.", "label": "Financial Advisory Fee Payable", "terseLabel": "Financial advisory fee payable" } } }, "localname": "FinancialAdvisoryFeePayable", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to founder.", "label": "Founder Shares", "terseLabel": "Founder Shares" } } }, "localname": "FounderSharesMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "domainItemType" }, "fhltu_FranchiseTaxExpense": { "auth_ref": [], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of franchise tax expense incurred during the period.", "label": "Franchise Tax Expense", "terseLabel": "Franchise tax expense" } } }, "localname": "FranchiseTaxExpense", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "fhltu_InitialBusinessCombinationTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Initial Business Combination Trading Day Period", "label": "Initial Business Combination Trading Day Period", "terseLabel": "Initial business combination trading day period" } } }, "localname": "InitialBusinessCombinationTradingDayPeriod", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "durationItemType" }, "fhltu_InitialInvestmentByFounder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of initial investment by the founders.", "label": "Initial Investment by the Founder", "terseLabel": "Initial investment by the founders" } } }, "localname": "InitialInvestmentByFounder", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Public Offering" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://futurehealthesgcorp.com/20220331", "xbrltype": "stringItemType" }, "fhltu_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about initial public offering.", "label": "Initial Public Offering [Text Block]", "terseLabel": "Public Offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOffering" ], "xbrltype": "textBlockItemType" }, "fhltu_MaximumAllowedDissolutionExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The maximum amount permitted to be paid for dissolution expenses if a business combination is not completed within the specified period.", "label": "Maximum Allowed Dissolution Expenses" } } }, "localname": "MaximumAllowedDissolutionExpenses", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum borrowing capacity of related party promissory note.", "label": "Maximum Borrowing Capacity of Related Party Promissory Note", "terseLabel": "Maximum borrowing capacity of related party promissory note" } } }, "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_MaximumCommonStockSharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the maximum number of common stock shares subject to forfeiture.", "label": "Maximum Common Stock Shares Subject To Forfeiture", "terseLabel": "Maximum shares subject to forfeiture" } } }, "localname": "MaximumCommonStockSharesSubjectToForfeiture", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "sharesItemType" }, "fhltu_MaximumLoansConvertibleIntoWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants.", "label": "maximum Loans Convertible Into Warrants", "terseLabel": "Loan conversion agreement warrant" } } }, "localname": "MaximumLoansConvertibleIntoWarrants", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_NumberOfPromissoryNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of promissory notes held.", "label": "Number of Promissory Notes", "terseLabel": "Number of promissory notes" } } }, "localname": "NumberOfPromissoryNotes", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails" ], "xbrltype": "integerItemType" }, "fhltu_NumberOfSharesIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares in a unit.", "label": "Number of Shares Issued Per Unit", "terseLabel": "Number of shares in a unit" } } }, "localname": "NumberOfSharesIssuedPerUnit", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "fhltu_NumberOfSharesIssuedToEachAnchorInvestor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued to each anchor investor.", "label": "Number of Shares Issued to Each Anchor Investor", "terseLabel": "Number of shares issued to each anchor investor" } } }, "localname": "NumberOfSharesIssuedToEachAnchorInvestor", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "fhltu_NumberOfSharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares owned by the founders subject to forfeiture if the underwriter overallotment option is not exercised in the proposed public offering.", "label": "Number Of Shares Subject To Forfeiture", "terseLabel": "Shares subject to forfeiture" } } }, "localname": "NumberOfSharesSubjectToForfeiture", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "fhltu_NumberOfWarrantsIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants in a unit.", "label": "Number of Warrants Issued Per Unit", "terseLabel": "Number of warrants in a unit" } } }, "localname": "NumberOfWarrantsIssuedPerUnit", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "fhltu_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available .", "label": "Numerator" } } }, "localname": "NumeratorAbstract", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "fhltu_OperatingBankAccounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating bank accounts.", "label": "Operating Bank Accounts", "terseLabel": "Operating bank accounts" } } }, "localname": "OperatingBankAccounts", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_OrdinarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Ordinary Shares [Member]", "terseLabel": "Common Stock" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "fhltu_OverallotmentOptionsPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Overallotment Options Period", "label": "Overallotment Options Period", "terseLabel": "Overallotment options period" } } }, "localname": "OverallotmentOptionsPeriod", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "durationItemType" }, "fhltu_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.", "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination", "terseLabel": "Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)" } } }, "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "fhltu_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.", "label": "Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant", "terseLabel": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant" } } }, "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "pureItemType" }, "fhltu_PercentageOfUnderwritingFeeOnGrossOfferingProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pe3rcentage of underwriting fees on gross offering proceeds.", "label": "Percentage of Underwriting Fee on Gross Offering Proceeds", "terseLabel": "Percentage of underwriting fees on gross offering proceeds" } } }, "localname": "PercentageOfUnderwritingFeeOnGrossOfferingProceeds", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "fhltu_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after filing within which the registration statement filed with the SEC is expected to become effective.", "label": "Period Of Time Within Which Registration Statement Is Expected To Become Effective", "terseLabel": "Period of time within which registration statement is expected to become effective" } } }, "localname": "PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "fhltu_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.", "label": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "domainItemType" }, "fhltu_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.", "label": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "domainItemType" }, "fhltu_RedeemablePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US\nAmount to be paid per share that is classified as redemption stock by holder only in the event of a change in control of the issuer.", "label": "Redeemable Price Per Share", "terseLabel": "Redeemable per share" } } }, "localname": "RedeemablePricePerShare", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "fhltu_RedeemableWarrantsExercisableForClassCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to redeemable warrants exercisable for class common stock", "label": "Redeemable warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50" } } }, "localname": "RedeemableWarrantsExercisableForClassCommonStockMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "fhltu_RedemptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption period.", "label": "Redemption Period", "terseLabel": "Redemption period" } } }, "localname": "RedemptionPeriod", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "fhltu_RelatedPartyLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for related party loans.", "label": "Related Party Loans" } } }, "localname": "RelatedPartyLoansMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "fhltu_RelatedPartyTransactionStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Related Party Transaction, Stock Issued During Period, Shares, New Issues", "terseLabel": "Aggregate sale of shares to founder" } } }, "localname": "RelatedPartyTransactionStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "fhltu_SaleOfStockOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering costs incurred.", "label": "Sale of Stock, Offering Costs", "terseLabel": "Offering costs" } } }, "localname": "SaleOfStockOfferingCosts", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_SaleOfStockOtherOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of other offering costs incurred.", "label": "Sale of Stock, Other Offering Costs", "terseLabel": "Other offering costs" } } }, "localname": "SaleOfStockOtherOfferingCosts", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_SaleOfStockUnderwritingDiscountsAndCommissions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering discounts and commissions incurred for underwriters.", "label": "Sale of Stock Underwriting Discounts and Commissions", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "SaleOfStockUnderwritingDiscountsAndCommissions", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_SaleOfStockUnderwritingFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering fees incurred and paid for underwriters.", "label": "Sale of Stock, Underwriting fees", "terseLabel": "Underwriting fees" } } }, "localname": "SaleOfStockUnderwritingFees", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_SecuritiesHeldInTrustAccount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of securities held in the Trust Account.", "label": "Securities Held In Trust Account", "terseLabel": "Securities held in Trust Account" } } }, "localname": "SecuritiesHeldInTrustAccount", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_SharePriceTriggerUsedToMeasureDilutionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The cutoff price used to measure whether dilution of the warrant has occurred. Shares issued below this price will cause the exercise price of the warrant to be adjusted.", "label": "Share Price Trigger Used To Measure Dilution Of Warrant", "terseLabel": "Share price trigger used to measure dilution of warrant" } } }, "localname": "SharePriceTriggerUsedToMeasureDilutionOfWarrant", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "perShareItemType" }, "fhltu_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for sponsor.", "label": "Sponsor" } } }, "localname": "SponsorMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "fhltu_StockPricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount refers to stock price per unit", "label": "Stock Price Per Unit" } } }, "localname": "StockPricePerUnit", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "fhltu_TemporaryEquityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for temporary equity.", "label": "Temporary Equity, Policy [Policy Text Block]", "terseLabel": "Common Stock Subject to Possible Redemption" } } }, "localname": "TemporaryEquityPolicyPolicyTextBlock", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fhltu_ThresholdBusinessDaysForRedemptionOfPublicShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Threshold Business Days for Redemption Of Public Shares", "terseLabel": "Threshold business days for redemption of public shares" } } }, "localname": "ThresholdBusinessDaysForRedemptionOfPublicShares", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "durationItemType" }, "fhltu_ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Threshold Minimum Aggregate Fair Market Value as Percentage Of Assets Held in Trust Account", "terseLabel": "Threshold minimum aggregate fair market value as percentage of assets held in trust account" } } }, "localname": "ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetsHeldInTrustAccount", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "fhltu_ThresholdNumberOfSpecifiedTradingDaysDeterminingVolumeWeightedAverageTradingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The threshold number of specified trading period determining volume weighted average trading price , in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Threshold Number of Specified Trading Days Determining Volume Weighted Average Trading Price", "terseLabel": "Threshold number of specified trading period determining volume weighted average trading price" } } }, "localname": "ThresholdNumberOfSpecifiedTradingDaysDeterminingVolumeWeightedAverageTradingPrice", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "fhltu_ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Threshold Percentage of Outstanding Voting Securities of Target to be Acquired by Post Transaction Company to Complete Business Combination", "terseLabel": "Threshold percentage of outstanding voting securities of target to be acquired by post transaction company to complete business combination" } } }, "localname": "ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "fhltu_ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Threshold Percentage of Public Shares Subject to Redemption Without Company's Prior Written Consent" } } }, "localname": "ThresholdPercentageOfPublicSharesSubjectToRedemptionWithoutCompanysPriorWrittenConsent", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "fhltu_ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time which must elapse after completion of a business combination before the Sponsor can transfer, assign or sell any Founder Shares unless other specified conditions are met.", "label": "Threshold Period For Not To Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination" } } }, "localname": "ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "durationItemType" }, "fhltu_ThresholdPeriodFromClosingOfPublicOfferingEntityIsObligatedToCompleteBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period from closing of public offering entity is obligated to complete Business Combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Threshold Period from Closing of Public Offering Entity is Obligated to Complete Business Combination", "terseLabel": "Threshold period from closing of public offering entity is obligated to complete Business Combination" } } }, "localname": "ThresholdPeriodFromClosingOfPublicOfferingEntityIsObligatedToCompleteBusinessCombination", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "durationItemType" }, "fhltu_TransactionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of transaction costs incurred.", "label": "Transaction Costs", "terseLabel": "Transaction Costs" } } }, "localname": "TransactionCosts", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days", "terseLabel": "Threshold period for not to transfer, assign or sell any Warrants" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "fhltu_TwelveAnchorInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Twelve anchor investors.", "label": "Twelve Anchor Investors" } } }, "localname": "TwelveAnchorInvestorsMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "domainItemType" }, "fhltu_UnderwritingCashDiscountPerUnit.": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount represents the cash underwriting discount per unit.", "label": "Underwriting Cash Discount Per Unit.", "terseLabel": "Underwriting cash discount per unit" } } }, "localname": "UnderwritingCashDiscountPerUnit.", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "fhltu_UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Unit each consisting of one class common stock .", "label": "Unit Each Consisting Of One Class Common Stock And One Third Redeemable Warrant" } } }, "localname": "UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "fhltu_UnitsIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new units issued during the period.", "label": "Units Issued During Period, Shares, New Issues", "verboseLabel": "Number of units issued" } } }, "localname": "UnitsIssuedDuringPeriodSharesNewIssues", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "fhltu_VariablePortionOfPercentageOfCashRetainedFromTrustAccountPaidToAdvisors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The variable portion of percentage of cash retained from the trust account (net of redemptions) paid to advisors.", "label": "Variable Portion Of Percentage Of Cash Retained From The Trust Account Paid To Advisors", "terseLabel": "Variable portion of percentage of cash retained from the trust account paid to advisors" } } }, "localname": "VariablePortionOfPercentageOfCashRetainedFromTrustAccountPaidToAdvisors", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "fhltu_WarrantExercisePeriodConditionOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after completion of a business combination before a warrant may be exercised.", "label": "Warrant Exercise Period Condition One", "terseLabel": "Warrant exercise period condition" } } }, "localname": "WarrantExercisePeriodConditionOne", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "fhltu_WarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for warrants.", "label": "Warrants, Policy [Policy Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsPolicyPolicyTextBlock", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "fhltu_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount represents the information about the working capital.", "label": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_WorkingCapitalLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of working capital loan outstanding.", "label": "Working Capital Loan", "terseLabel": "Working capital loan, outstanding" } } }, "localname": "WorkingCapitalLoan", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "fhltu_WorkingCapitalLoansWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loans warrant.", "label": "Working capital loans" } } }, "localname": "WorkingCapitalLoansWarrantMember", "nsuri": "http://futurehealthesgcorp.com/20220331", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r133", "r140", "r166", "r167", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r258", "r259", "r268", "r269" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r133", "r140", "r166", "r167", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r258", "r259", "r268", "r269" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r133", "r140", "r164", "r166", "r167", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r258", "r259", "r268", "r269" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r133", "r140", "r164", "r166", "r167", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r258", "r259", "r268", "r269" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r22", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r10", "r243", "r251" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Franchise tax payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r172", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r60", "r61", "r62", "r169", "r170", "r171", "r195" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r56", "r103", "r105", "r109", "r113", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r187", "r191", "r201", "r217", "r219", "r242", "r250" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r7", "r30", "r56", "r113", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r187", "r191", "r201", "r217", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Marketable securities held in Trust Account", "verboseLabel": "Marketable securities held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [TEXT BLOCK]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r20", "r219", "r265", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r20", "r50" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash held outside the Trust Account", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r9", "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r45", "r50", "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash - end of period", "periodStartLabel": "Cash - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r45", "r202" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r20" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash FDIC Insured Amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r54", "r56", "r76", "r77", "r78", "r81", "r83", "r89", "r90", "r91", "r113", "r122", "r126", "r127", "r128", "r131", "r132", "r138", "r139", "r143", "r147", "r201", "r275" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r162", "r168" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares issuable per warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Sale of Private Placement Warrants (in shares)", "verboseLabel": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r162", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r27", "r120", "r245", "r254" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 5):" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r117", "r118", "r119", "r121", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r60", "r61", "r195" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value, (per share)", "verboseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, shares authorized", "verboseLabel": "Common shares, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 5,000,000 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r95", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Offering Costs", "terseLabel": "Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r38", "r65", "r66", "r67", "r68", "r69", "r73", "r76", "r81", "r82", "r83", "r86", "r87", "r196", "r197", "r247", "r257" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic net income per share", "verboseLabel": "Income/(Loss) earning per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r38", "r65", "r66", "r67", "r68", "r69", "r76", "r81", "r82", "r83", "r86", "r87", "r196", "r197", "r247", "r257" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share", "verboseLabel": "Income/(Loss) earning per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share of Common Stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r57", "r176", "r185" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Pre-Tax Book Loss (in percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r34", "r35", "r36", "r60", "r61", "r62", "r64", "r70", "r72", "r88", "r114", "r154", "r161", "r169", "r170", "r171", "r183", "r184", "r195", "r203", "r204", "r205", "r206", "r207", "r208", "r260", "r261", "r262", "r278" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r41", "r48", "r112" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "negatedLabel": "Gain on marketable securities (net), dividends and interest, held in Trust Account", "terseLabel": "Gain on marketable securities (net), dividends and interest, held in Trust Account" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r33", "r174", "r175", "r179", "r180", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r47" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r47" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r40", "r102" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Interest income", "verboseLabel": "Interest income on cash balance" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r56", "r106", "r113", "r122", "r123", "r124", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r188", "r191", "r192", "r201", "r217", "r218" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r56", "r113", "r201", "r219", "r244", "r253" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Common Stock Subject to Possible Redemption, and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION, AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r56", "r113", "r122", "r123", "r124", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r188", "r191", "r192", "r201", "r217", "r218", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r3", "r24" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities held in trust" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r92", "r101" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK]", "terseLabel": "Description of Organization and Business Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r45" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r45", "r46", "r49" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r31", "r32", "r36", "r37", "r49", "r56", "r63", "r65", "r66", "r67", "r68", "r71", "r72", "r79", "r103", "r104", "r107", "r108", "r110", "r113", "r122", "r123", "r124", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r197", "r201", "r246", "r256" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r65", "r66", "r67", "r68", "r73", "r74", "r80", "r83", "r103", "r104", "r107", "r108", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Allocation of net income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r58", "r212", "r255" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties.", "label": "Notes Payable, Related Parties", "terseLabel": "Outstanding balance of related party note" } } }, "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r103", "r104", "r107", "r108", "r110" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization and Business Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-allotment option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r138" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value, (per share)", "verboseLabel": "Preferred stock, par value, (per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred shares, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r138" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred shares, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred shares, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitPreferredStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r6", "r115", "r116" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance initial public offering", "terseLabel": "Proceeds from issuance initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r42" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock to Sponsor", "verboseLabel": "Cash from issuance of shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from sale of Private Placement Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "verboseLabel": "Proceeds from IPO and Private Placement Warrants" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r43" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Amount borrowed", "verboseLabel": "Advances from related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r31", "r32", "r36", "r44", "r56", "r63", "r71", "r72", "r103", "r104", "r107", "r108", "r110", "r113", "r122", "r123", "r124", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r186", "r189", "r190", "r193", "r194", "r197", "r201", "r248" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r165", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r165", "r211", "r212", "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r165", "r211", "r214", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r209", "r210", "r212", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r161", "r172", "r219", "r252", "r263", "r264" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r60", "r61", "r62", "r64", "r70", "r72", "r114", "r169", "r170", "r171", "r183", "r184", "r195", "r260", "r262" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Purchase price of share by anchor investor", "verboseLabel": "Sale price of the Class A common stock equals or exceeds" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Reconciliation of Net Loss per Common Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsRelatedPartyLoansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r28", "r54", "r89", "r90", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r147", "r152", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Purchase price, per unit" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r54", "r56", "r76", "r77", "r78", "r81", "r83", "r89", "r90", "r91", "r113", "r122", "r126", "r127", "r128", "r131", "r132", "r138", "r139", "r143", "r147", "r154", "r201", "r275" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/DocumentDocumentAndEntityInformation", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r29", "r34", "r35", "r36", "r60", "r61", "r62", "r64", "r70", "r72", "r88", "r114", "r154", "r161", "r169", "r170", "r171", "r183", "r184", "r195", "r203", "r204", "r205", "r206", "r207", "r208", "r260", "r261", "r262", "r278" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED STATEMENTS OF CHANGES IN COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r60", "r61", "r62", "r88", "r229" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfCashFlows", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r154", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock to Sponsor (in shares)", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r154", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock to Sponsor", "verboseLabel": "Aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r56", "r111", "r113", "r201", "r219" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r55", "r139", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r153", "r161", "r163" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfChangesInCommonStockSubjectToPossibleRedemptionAndStockholderSEquityDeficitParenthetical", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosurePublicOfferingDetails", "http://futurehealthesgcorp.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r122", "r126", "r127", "r128", "r131", "r132" ], "calculation": { "http://futurehealthesgcorp.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "verboseLabel": "Common stock subject to possible redemption, 20,000,000 shares at $10.05 per share" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r8", "r135" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "verboseLabel": "Common shares, redemption value per share | $ / shares" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares outstanding", "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)", "verboseLabel": "Common shares, shares subject to possible redemption" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitCommonStockDetails", "http://futurehealthesgcorp.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r173", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "verboseLabel": "Unrecognized tax benefits accrued for interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r93", "r94", "r96", "r97", "r98", "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureDescriptionOfOrganizationAndBusinessOperationsDetails", "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Public Warrants expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureStockholdersDeficitWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r75", "r83" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r73", "r83" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://futurehealthesgcorp.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerCommonShareDetails", "http://futurehealthesgcorp.com/role/StatementUnauditedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r271": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r272": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r273": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r274": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r275": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r276": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r277": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" } }, "version": "2.1" } ZIP 47 0001410578-22-000917-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410578-22-000917-xbrl.zip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end